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Asukamycin, a member of the manumycin family metabolites, is an antimicrobial and 
potential antitumor agent isolated from Streptomyces nodosus subsp. asukaensis. The entire 
asukamycin biosynthetic gene cluster was cloned, assembled and expressed heterologously in 
Streptomyces lividans. Bioinformatic analysis and mutagenesis studies elucidated the 
biosynthetic pathway at the genetic and biochemical level. Four gene sets, asuA-D, govern the 
formation and assembly of the asukamycin building blocks, a 3-amino-4-hydroxybenzoic acid 
(3,4-AHBA) core component, a cyclohexane ring, two triene polyketide chains and a 2-amino-3-
hydroxycyclopent-2-enone (C5N) moiety to form the intermediate protoasukamycin. AsuE1 and 
AsuE2 catalyze the conversion of protoasukamycin to 4-hydroxyprotoasukamycin, which is 
epoxidized at C5-C6 by AsuE3 to the final product, asukamycin. Branched acyl CoA starter 
units, derived from Val, Leu and Ile, can be incorporated by the actions of the polyketide 
synthase KSIII AsuC3/C4 as well as the cellular fatty acid synthase FabH to produce the 
asukamycin congeners A2-A7. In addition, the type II thioesterase AsuC15 limits the cellular 








Discovery of Manumycin Metabolites 
The manumycin family of metabolites contains 34 members, and continues to expand due 
to the ongoing discovery of novel natural products. The first member, manumycin A, was 
isolated from Streptomyces parvulus Tü 64 in 1963 [1]. Revealed by Zeeck group, the chemical 
structure of manumycin A features two polyketide chains (Fig. 1.1) [2]. The “lower” trans triene 
chain starts with a 2-amino-4-hydroxy-5,6-epoxycyclohex-2-enone (mC7N) core and terminates 
into a five-membered ring, 2-amino-3-hydroxycyclopent-2-enone (C5N) moiety; the “upper” one 
consists of methyl branched polyketide, amide-linked to the mC7N core. The stereochemistry of 
this compound was first presented by Thiericke group [3, 4], and later revised by Taylor and co-
workers [5]. 
Asukamycin (A1) was discovered in the fermentation culture of Streptomyces nodosus 
subsp. asukaensis by Omura et al. in 1976 (Fig. 1.1) [6]. Elucidated by Omura and Floss groups, 
asukamycin shares the entire lower chain with manumycin A, while it differs at the upper one, a 
trans triene polyketide initiated with a characteristic cyclohexane moiety [7, 8]. Soon after the 
discovery of asukamycin, twenty-one novel manumycin compounds including the type II form of 
colabomycin D and manumycin D were subsequently identified during 1980s and 1990s (Table 
1). These type II manumycins contain a hydroxyethylene group to replace the epoxy moiety at 
the C5-C6 position of the mC7N core. Scrutinizing the metabolic profile of S. nodosus, Floss and 
colleagues have identified six more asukamycin congeners, manumycin G (A2), El-1511-5 (A3), 
U-56,407 (A4), manumycin E (A5), asukamycin F (A6), asukamycin G (A7), plus five type II 
asukamycins, B1-B5 (Fig. 1.1) [6, 9, 10]. In the same study, a series of unnatural asukamycin 
analogs, containing various cyclic ring structures to substitute the cyclohexane moiety were 
3 
obtained through the feeding experiments with the variable ring-sized alicyclic carboxylates in S. 




Figure 1.1 Molecular structure of manumycin A, asukamycin, and congeners. Type I and II 
metabolites are grouped according to the main core units of A and B, respectively. 
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Table 1.1 Structures of manumycin family metabolites. 
Compounds Stereochemistry R1 R2 References 
Type Ia 
Manumycin A 4S, 5R, 6S* 
 
 
[2-4, 11, 12] 
Manumycin B  4S, 5R, 6S* 
 
[11-14] 
Manumycin C  4S, 5R, 6S 
 
[11-14] 
EI-1625-2  4S, 5R, 6S* 
 
[14-17] 

















[10, 22, 23] 
Manumycin F  






4S, 5 and 6 not 
determined 
 
[10, 17, 22, 23] 
U-56, 407 (A4)  4S, 5R, 6S 
 
[10, 24, 25] 






































Ent-alisamycin 4S, 5R, 6S 
 
[14-17] 
EI-1511-3  4S, 5R, 6S 
 
[14-17] 

















TMC-1A 4S, 5R 
 
[11] 
TMC-1B  4S, 5R 
 
[11] 
TMC-1C  4S, 5R 
 
[11] 



































Structure and Classification 
Manumycin metabolites were categorized into two classes based on the structure of the 
mC7N core moiety (Fig. 1.2). While the type I manumycins contain an oxirane at the C5-C6 
position, a ring-opened hydroxyethylene was adopted by the type II compounds, which are likely 
originated from their type I counterparts through an enzymatic /or non-enzymatic path (Fig. 1.2). 
For example, the crude extract of asukamycin (A1) can be gradually reduced to the asukamycin 
A-II (B1) under room temperature. To the type I form of manumycins, the mC7N core mostly 
displays a 4S, 5R, 6S stereochemistry except for nisamycin and alisamycin, exhibiting a 4R, 5S, 
6R configuration. Notably, the mC7N configuration was incorrectly assigned as a 4R, 5R, 6S for 
manumycin A, manumycin B and EI-1625-2 in an early study. As manumycin A revealed an 
opposite pattern of the optical rotation and CD spectrum compared with that of the synthesized 
ent-(+)- manumycin A, the chirality of manumycin A has been revised to 4S, 5R, 6S. In this 
study, we have identified two new classes besides type I and II manumycins, the proto-type (C1-
C5) and the 4-hydroxyproto-type (D1-D5), featuring with an aromatic and a hydroxyquinol 
cores, respectively (see chapter 6). 
Based on the chain length and the degree of saturation of the lower polyketide chain, the 
type I manumycins are further divided into three subgroups. Type Ia, Ib, and Ic feature the 
corresponding trans triene, tetraene, and saturated polyketides. The majority of manumycin 
compounds belong to the type Ia subfamily, while colabomycin A and U-62,162 are the only 
reported type Ib and Ic manumycins, respectively. Correspondingly, a majority of the type II 
manumycins belong to the type IIa subgroup with one exception of the unique IIb member, 
colabomycin D. Besides, most manumycins contain a lower polyketide chain amide-linked with 
7 
a C5N moiety except for nisamycin and U-62,162, carrying a free carboxylic group without the 
C5N moiety attached. 
 
 
Figure 1.2 Classification of manumycins. The proto-type and the pre-type compounds are 




Manumycin metabolites have been identified mostly through the antibiotic screening 
based on their broad antimicrobial actions including the antibacterial (Gram-positive), 
anticoccidial, and antifungal activities [38]. Manumycin A also exhibits the insecticidal activity 
[39]. Although the detailed mechanism has yet been fully understood, the epoxyquinol moiety of 
the mC7N core likely plays an essential role for these antimicrobial activity, as the type II 
manumycins, TMC-1A-D and manumycin D, failed to show the effectiveness against the Gram-
positive or Gram-negative bacteria [11]. Interestingly, nisamycin, lacking a C5N moiety, 
displayed 6-fold higher antibacterial potency than its C5N-containing analog, alisamycin. This 
observation indicated that the presence of the C5N moiety might not be critical in view of the 
biological activity [33]. Furthermore, the derivatives of nisamycin with an amide-linkage to an 
alkane, a cycloalkane, or an arene also reduced its antimicrobial activity. 
Anticancer Activity  
Manumycin compounds are known for the anticancer function against various tumors in 
vitro and in vivo [38]. Manumycin A has been proved to inhibit the progression of the human 
fibrosarcoma HT1080 tumor cells in the transplanted mice [40]. Two other studies showed that 
the human pancreatic cancer was significantly suppressed in vivo by the manumycin A treatment 
without having apparent hepatotoxicity [41, 42]. In addition, manumycin A also displayed the 
antiangiogenesis ability in mice transplanted with the hypoxic Anaplastic thyroid cancer (ATC) 
cells, likely by limiting the vascular endothelial growth factor [43, 44]. A triple drug “cocktail”, 
manumycin A, combretastatin A4 phosphate (CA4P), and paclitaxel developed by Yeung and 
9 
co-workers, assured a great promise in the treatment of several ATC cell lines without showing a 
significant toxicity in mice [43, 45, 46].  
Despite the elusive mechanism behind these anticancer activities, some manumycin 
metabolites seem to elicit the cell death through the inhibition of the RAS farnesyltransferase 
(FTase). RAS FTase catalyzes the linkage between a farnesyl pyrophosphate and the C-terminal 
Cys residue of RAS, an essential modification step to anchor the RAS to the cellular membrane 
for its function. As a binary enzyme switching between the active and inactive form, RAS 
protein is a key player to regulate the cell growth and malignant transformation. The mutation of 
ras oncogene frequently results in its consistent activation, which is associated with 30% to 50% 
of lung and colon carcinomas and up to 90% of human pancreatic cancers. Thus, one 
chemotherapeutic treatment for these cancers is to suppress the RAS activity by inhibiting the 
RAS FTase [47]. For example, manumycin A has been shown to slow down the growth of 
human hepatoma cell line via inhibiting the Ras activity [48]. Moreover, manumycin A, B, and C 
specifically inhibit the FTase activity but not the closely-related geranylgeranyltransferase 
(GGTase), which allows the normal cell to survive by bypassing the FTase deficiency through 
GGTase [40, 49]. Due to a high potency against the tumor cells but a low cytotoxicity towards 
the normal cells, these compounds hold great promise in the chemotherapeutic application. 
Besides the inhibition of RAS FTase, manumycin A can trigger the cell death through 
some FTase-independent pathways. One study showed that manumycin A caused the death of 
the breast cell lines and thyroid cells by induction of the reactive oxygen species (ROS), such as 
nitric oxide (NO•) and superoxide anion (•O2
-
), triggering the downstream caspase-independent 
dsDNA breakages [50]. Another report claimed that manumycin A stimulated apoptosis of 
lymphoid tumor and myeloma cell lines due to the caspase-dependent ROS induction [51]. Most 
recently, the manumycin family compounds have been confirmed to suppress the oncogenesis by 
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inhibiting the IκB kinase β (IKKβ) activity, possibly through a covalent dimerization of IKKβ 
[52]. These findings provided more information on how the cancer cells were killed by the 
manumycin compounds.  
Inhibition of Interleukin-1β Converting Enzymes 
Interleukin-1β converting enzymes cleave the inflammatory cytokines, interleukin-1β and 
interleukin 18, to generate the active form of peptides to trigger the inflammatory cascade. 
Manumycin metabolites, EI-1511-3, -5, EI-1625-2, manumycin A, B, G, U-56,407, and ent-
alisamycin, reveal not only the inhibitory activity against interleukin-1β converting enzymes, but 
also suppress the secretion of interleukin-1β [16, 53]. Notably, the inhibition of the interleukin-
1β secretion but not for the interleukin-1β converting enzymes is no longer sustained, once the 
lower polyketide and a C5N moiety of these manumycin compounds were removed. 
Inhibition of Acetylcholinesterase 
Recently, manumycin A, B and C were found to serve as a specific acetylcholinesterase 
(AChE) inhibitor, which might lead to potential drug development for Alzheimer’s disease 
treatment [54]. Found in the neuromuscular junctions and cholinergic synapses of the central 
nervous system, AChE catalyzes the degradation of the neurotransmitter, acetylcholine (ACh), to 
give choline and acetate to terminate the synaptic transmission. Thus, the AChE inhibitor can 
boost the cholinergic synapse activity via the increasing ACh availability.  Manumycin A, B and 
C could inhibit the AChE comparable to the commercial available Tacrine (Cognex®, 1993) but 
with much better specificity, as these three compounds did not exhibit any inhibitory activity on 
butyrylcholinesterase (BuChE), which causes Tacrine’s major hepatotoxic side effects during 
therapeutic treatment. The epoxide of the mC7N core likely plays an essential role, as 




The biosynthetic study of manumycin compounds has been focusing on manumycin A 
and asukamycin. These two compounds may reflect the biosynthesis of other family member, as 
a majority of the manumycin metabolites share an identical lower triene polyketide, primed with 
an mC7N core and ended up with a C5N ring. A rational biosynthetic route has been proposed in 
according to a series of chemical feedings, while little biochemical or genetic data was available 
before this study except for the cloned 5-aminolevulinic acid synthase (ALAS) gene published 
by Petricek group [21]. 
mC7N Core 
The mC7N core moiety of manumycin metabolites arises from 3-amino-4-
hydroxybenzoic acid (3,4-AHBA) instead of 3-amino-5-hydroxybenzoic acid (3,5-AHBA), the 
common building block for ansatrienin A, rifamycin B and mitomycin C [55]. Feeding labeled 
3,4-AHBA, Zeeck group has first isolated the 64-3,4-AHBA2, a proto-type of manumycin A in 
the culture of S. parvulus Tü 64 [56, 57]. Gould and co-workers proposed that 3,4-AHBA is the 
real precursor of manumycin compounds [58], and Floss group further confirmed this 
speculation through a successful feeding of 3,4-AHBA to asukamycin and manumycin A [19]. In 
addition to manumycins, 3,4-AHBA is also a biosynthetic precursor for 4-hydroxy-3-
nitrosobenzamide and grixazone found in Streptomyces murayamaensis and Streptomyces 
griseus, respectively (Fig. 1.3) [58, 59].  
Polyketide Chains and the Cyclohexane Moiety 




C]-acetate indicated that the 
lower and upper trienes were built up using three malonyl CoA extenders through the polyketide 
condensations (Figure 1.4) [60]. The polyketide-derived biosynthesis was also supported by the 
12 




O]-acetate at C-13 and C-1’ position in asukamycin. Despite 
these, it is unclear whether a multi-domain type I or an iterative type II polyketide synthases 
(PKS) with discrete functional units is involved in the chain assembly. 
 
Figure 1.3 3,4-AHBA derived natural products. 3,4-AHBA is the common precursor of 
manumycins, grixazones, and 4-hydroxy-3-nitrosobenzamide. 
 
Figure 1.4 Biosynthetic origin of asukamycin. 
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Feeding pattern of labeled glycerol demonstrated that the origin of the cyclohexane 
moiety, CHC-CoA, is derived from shikimic acid [60]. In fact, this cyclohexane moiety has been 
widely found in other natural products, such as ansatrienin [61], doramectin [62], 
phoslactomycin [63], all of which were proved to arise from the shikimate pathway via the 
chemical feeding and genetic studies (Fig. 1.5). A gene set, ansJKLM/chcA, involved in the 
CHC-CoA biosynthesis of ansatrienin has been well characterized in Streptomyces collinus [62]. 
Additionally, Floss and co-workers has managed to generate a series of novel manumycin 
compounds, such as cyclopropyl-, cyclobutyl-, cyclopentyl- and cycloheptyl-asukamycin by 
feeding with various ring sizes of carboxylates to S. nodosus (Table 1.1).  
Alternatively, the CHC-CoA can also be recruited to form ω-cyclohexyl fatty acids as a 
part of cellular membrane components in S. nodosus subsp. asukaensis (Fig. 1.5) [10]. Notably, 
the incorporation of CHC-CoA to give cyclohexyl fatty acids also occurs in other 
microorganisms, including the Alicyclobacillus acidocaldarius and the ansatrienin producer S. 
collinus [62, 64]. As the membrane fluidity and permeability are strongly determined by the fatty 
acid composition, the biosynthetic regulation of each fatty acid component is crucial for 
membrane homeostasis in bacteria [65, 66]. The content of ω-cyclohexyl fatty acids, a byproduct 
generated during the peak period of asukamycin biosynthesis, is maintained to be as low as 3% 
[10]. This implies that the organism has a control mechanism to balance the metabolic flux 
between the production of membrane fatty acids and asukamycin. 
The C5N Moiety 
The lower polyketide chain of asukamycin terminates with a 2-amino-3-
hydroxycyclopent-2-enone (C5N) moiety, an enol tautomer of the 2-aminocyclopentanedion. 
This nitrogen-containing five membered cyclic ring also serves as a structural component in 




Figure 1.5 CHC-CoA derived natural products. 
  
15 
bafilomycin B1, ECO-02301, ECO-0501, and the majority of manumycin metabolites (Fig. 1.6) 
[21, 67-72]. Feeding experiments illustrated that a glycine and a succinyl-CoA are the building 
blocks for this C5N moiety (Fig. 1.4) [60, 73]. Moreover, the labeled 5-aminolevulinate (5-ALA) 
was found to be incorporated in a low efficiency to the reductiomycin biosynthesis of 
Streptomyces xanthochromogenus, implying that 5-ALA could be a close precursor of the cyclic 
C5N structure.  
5-ALA is an essential precursor for the assembly of tetrapyrrole, which is further 
converted to hemes, chlorophylls, billins and corrinoids in many organisms  [74]. Two 
biosynthetic routes have been described to form this primary metabolite (Fig. 1.7). In plants and 
many bacteria, 5-ALA arises from a glutamate-tRNA through the C5 pathway, which requires the 
consecutive actions of a glutamyl-tRNA
Glu
 reductase (Gtr) and a glutamate-1-semialdehyde 2,1-
aminomutase [75]. To animals, fungi, and some other bacteria, the 5-ALA formation is governed 
by the Shemin pathway, where the 5-ALA synthase catalyzes the condensation between a 
glycine and a succinyl-CoA to give 5-ALA [75]. S. nodosus subsp. asukaensis employs the C5 
pathway to form 5-ALA, as the growth of the gtr mutant highly relies on the addition of 5-ALA 
to the culture [21]. 
Encoding a putative 5-ALA synthase to catalyze the condensation between a glycine and 
a succinyl-CoA, the cloned hemA-asuA (herein named as asuD2) is essential for the asukamycin 
biosynthesis, as the asuD2 mutant failed to produce asukamycin in S. nodosus [21]. Interestingly, 
neither the accessible C5 pathway can compensate the asuD2 deficiency to continue the 
production of asukamycin; nor the AsuD2 is capable of providing a sufficient 5-ALA to sustain 
the survival of the gtr mutant (Fig. 1.7). These seemingly contradictory observations implied that 
AsuD2 might have an unknown or additional functional activity compared with other 
characterized 5-ALA synthases. 
16 
 
Figure 1.6 Examples of natural products containing C5N moiety. The C5N moieties are 






Figure 1.7 C5 and Shemin pathways for the 5-ALA formation. The question marks indicate 
the dubious steps. The dashed arrow and enzyme indicate the standard 5-ALA synthase that 
might not present in S. nodosus. 
 
To date, the mechanism behind the intramolecular cyclization of the C5N moiety remains 
to be clarified. Besides, the amino group of C5N moiety is mostly acylated through an amide 
bond to a polyenoic acid component of polyketide, with the exception of moenomycin A (Fig. 
1.6). The amide-forming enzyme committed in this step is still unknown. Due to the stability 
issues, there has yet been a successful feeding experiment using a C5N or its derivatives such as 
2-amino-3-hydroxycyclopent-2-enone, or 2-amino-3-hydroxycyclopent-2-enone hydrochloride 
(Hu Y., Floss H., unpublished). 
The Oxygenation of Protoasukamycin to Form Asukamycin 
The two oxygen atoms, positioned in the C4 hydroxyl group and the C5-C6 epoxy group, 
had been proved to arise from the atmosphere O2 through the feeding experiment (Fig. 1.4) [76]. 
18 
Notably, all the isolated manumycin metabolites from each individual producing organism 
feature a unique stereochemistry with either all 4S, 5R, 6S or all 4R, 5S, 6R. For example, both S. 
parvulus and S. nodosus generate an identical 4S, 5R, 6S core of manumycins and asukamycins, 
while alisamycin and nisamycin, characterized with a 4R, 5S, 6R configuration, are solely found 
in Streptomyces K106. These observations strongly suggested that the oxygenation does not 
occur spontaneously, and likely requires the involvement of enzymes. 
The 
13
C-labeled feeding study has shown that protoasukamycin C1 is the precursor of 
asukamycin A1 in S. nodosus subsp. asukaensis [20]. The structure analysis indicates that the 2-
amino-4-hydroxy-5,6-epoxycyclohex-2-enone core of asukamycin bears a resemblance with the 
epoxyquinone moiety of the Vitamin K-2,3-epoxide and LL-C10037R, in which the epoxide 
oxygen atom is recruited from the atmosphere O2 through the action of a dioxygenase 
dihydrovitamin K epoxidase and a 2,5-dihydroxyacetanilide epoxidase respectively (Fig. 1.8) [9, 
20, 38, 77-80]. Nevertheless, the 
18
O2 feeding has specified that the hydroxyl and the epoxide 
oxygen atoms positioned at the C4 and C5-C6 positions of manumycin A were incorporated 
independently from the air oxygen, possibly through a two-step oxygenation mechanism in S. 
parvulus Tü 64 [76]. 
Research Objects 
1. Identification of the Asukamycin Biosynthetic Genes 
(1) To find the conserved gene probes to identify the asu genes. 
(2) To clone and sequence the asu genes from a cosmid library. 
(3) To functionally express the entire asu cluster in a heterologous strain. 
(4) To justify a minimal set of the asu gene cluster.  
2. Genetic and Biochemical Studies of the asu Genes  
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Figure 1.8 Previously proposed dioxygenase mechanism for asukamycin biosynthesis based 
on the formation of Vitamin K oxide and LL-C10037α. 
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 (1) Genes involved in the biosynthesis of the 3,4-AHBA core. 
(2) Genes responsible for the C5N moiety formation. 
(3) Genes in control the assembly of the upper and lower triene polyketides. 
(4) Genes acting on the formation of two amide bond linkages.  
(5) Genes governing the oxygenation of protoasukamycin to give asukamycin. 
3. Characterization of the Asukamycin Biosynthetic Pathway. 
(1) To explore the novel intermediates and pathway related products. 
(2) To determine the timing for the assembly of the building blocks. 
(3) To dissect the biosynthetic routes for asukamycin and its congeners. 
(4) To investigate the interaction between the formations of asukamycin and the cellular fatty 
acids. 
(5) To assess and revise the current biosynthetic model. 
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CHAPTER TWO:  
 
IDENTIFICATION AND CHARACTERIZATION OF THE ASUKAMYCIN 
BIOSYNTHETIC GENE CLUSTER 
22 
Introduction 
Owing to the accumulated genetic and biochemical data, the biosynthetic genes for a 
natural product can be targeted from the genomic library using a DNA probe, designed and 
amplified based on a conserved protein involved in the assembly of a similar structural moiety. 
For example, genes coding for TDP-D-glucose 4,6-dehydratase and halogenase were used to fish 
the biosynthetic gene clusters of kanamycin and kutzneride, respectively [81, 82]. As secondary-
metabolite biosynthetic genes tend to be clustered in prokaryotes, the identification of one gene 
could lead to the revealing of the entire gene cluster in its vicinity. 
Asukamycin contains several characteristic structural moieties, such as a cyclohexane 
group, a C5N ring, an mC7N core, and two triene polyketides. Due to the specificity problem of 
the polyketide synthases (PKS), it could be difficult to pinpoint the dedicated genes for the triene 
formation, particularly in the presence of many irrelevant PKSs involved in the biosynthesis of 
other secondary polyketide metabolites. The genes responsible for the formation of a unique 
cyclohexane group can be targeted by the gene set, ansJKLM/chcA, which had been proved to 
govern the CHC-CoA assembly in ansatriene biosynthesis [62]. To target the C5N moiety, we 
can choose either the asuD2, the only gene reported to condense the glycine and succinyl-CoA 
precursors in the asukamycin biosynthesis.   
Results 
Identification and Cloning of the Asu Cluster  
To identify the asukamycin biosynthetic gene cluster, a cosmid genomic library of S. 
nodosus subsp. asukaensis was constructed and screened with two 
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P-labelled DNA probes. 
Encoding the 1-cyclohexenylcarbonyl CoA reductase involved in the assembly of cyclohexane 
moiety for the ansatrienin biosynthesis in Streptomyces collinus, the chcA identified two 
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cosmids, 2B9 and 10D6, which revealed a 1.8 kb overlapping region of the cloned DNA inserts 
[62]. Encoding a 2-oxoamine synthase for the C5N moiety formation of asukamycin, the asuD2 
only hybridized with cosmid 10D6 [21]. As cosmid 10D6 was picked out by both probes, we 
predicted that the overlapping 10D6 and 2B9 likely covers large part of the asukamycin 
biosynthetic gene cluster. Thus, these two cosmids were mapped and sequenced to disclose a 
total combined 63,922 bp of DNA inserts (GeneBank accession No. GQ926890). DNA sequence 
analysis revealed 36 potential open reading frames, tentatively assigned as the asu genes, 
encoding for the gene products potentially involved in the asukamycin biosynthesis and 
regulatory activities (Fig. 2.1 and Table 2.1). 
Heterologous Expression of the Asu Cluster  
DNA analysis has preliminarily allocated the crucial genes required for the compilation 
of the building blocks (asuA-E groups), such as the 3,4-AHBA, the cyclohexanyl carboxylate 
and the 2-amino-3-hydroxy-cyclopent-2-enone (C5N) components, the upper and lower 
polyketide chains assembly, and the post-assembly oxygenation of the protoasukamycin. Also 
proposed were the genes tentatively involved in the regulation (asuR) and the exportation of the 
newly formed asukamycin metabolites outside the cells (asuM1). To confirm that the cloned 
region contained all the genes in control of the biosynthesis, regulation and self-immunity, a 
series of heterologous expression experiments were conducted in the asukamycin nonproducing 
Strptomyces lividans K4-114. Because neither of the cloned cosmids carried the full gene sets 
mentioned above, we intended to reassemble the cosmids 2B9 and 10D6 into one single clone. 
To combine two large DNA fragments, the conventional digestion/ligation cloning 
strategy has several shortcomings. For example, the choice of a unique cloning restriction site 







Figure 2.1. Open reading frames identified in the asu cluster. The putative genes were divided into eight groups based on the 
functional characterization. Group A: 3,4-AHBA biosynthesis and adenylation; Group B: CHC-CoA biosynthesis; Group C: 
polyketide chain assembly; Group D: C5N moiety biosynthesis; Group E: oxygenation; Group R: transcriptional regulation; 
AsuM1: efflux protein. The relative genomic regions and overlapping inserts of three cosmid clones 2B9, 10D6, pART1361, and 
pART1391 are indicated with bold lines.  
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Table 2.1 Deduced functions of ORFs in the asukamycin biosynthetic gene cluster. 
 
Protein aa Homolog (Accession No.) Identified or Proposed Function 
AsuA1 372 GriH (YP_001825760.1) 3,4-AHBA synthase 
AsuA2 471 ACMS I (AAD30111.1) 3,4-AHBA carboxyl group adenylation 
AsuA3 278 GriI (BAF36651.1) Condensation of ASA and DHAP 
AsuB1 983 PlmJK (AAQ84158.1) EPSP synthase/CHC-CoA ligase 
AsuB2 394 PlmL (AAQ84159.1) Acyl-CoA dehydrogenase 
AsuB3 277 ChcA (AAC44655.1) 1-cyclohexenylcarbonyl CoA reductase 
AsuB4 667 PlmM (AAQ84161.1) 2,4-dienoylCoA reductase 
AsuC1 219 Sfp (pdb|1QR0) Phosphopantetheinyl transferase 
AsuC2 269 GdmF (AAO06919.1)  Arylamine N-acyltransferase 
AsuC3 338 ZhuH (pdb|1MZJ) Asukamycin ketosynthase III 
AsuC4 361 ZhuH (pdb|1MZJ) Asukamycin ketosynthase III 
AsuC5 84 ZhuG (AAG30194.1) Asukamycin KSIII associated ACP 
AsuC6 151 PaaI (P76084) Thioesterase 
AsuC7 234 Sco1815 (pdb|2NM0) Ketoreductase 
AsuC8 152 HadC (NP_215151.1) Acyl dehydratase 
AsuC9 150 HadB (YP_001281933.1) Acyl dehydratase 
AsuC10 94 Putative ORF Unknown 
AsuC11 91 ZhuN (AAG30201.1) KSI/II associated ACP 
AsuC12 87 AcmACP (AAD30112.1)  3,4-AHBA carrier protein 
AsuC13 397 FabF(pdb|2GQD) Asukamycin ketosynthase I/II 
AsuC14 240 FabF (pdb|2GQD) Asukamycin ketosynthase I/II 
AsuC15 260 RifR (pdb|3FLB) Type II thioesterase 
AsuR1 242 GerE (pdb|1FSE) Transcriptional regulation 
AsuR2 191 TetR family protein Transcriptional regulation 
AsuR3 307 Membrane protein Transcriptional regulation 
AsuR4 141 DNA-binding protein Transcriptional regulation 
AsuR5 254 FarR3 (BAG74713.1) Transcriptional regulation 
AsuH1 384 Putative ORF Unknown 
AsuR6 280 GerE (pdb|1FSE) Transcriptional regulation 
AsuE1 407 PHBH (pdb|1YKJ) Protoasukamycin 4-hydroxylase 
AsuE2 185 PheA2 (pdb|1RZ0)  Flavin Reductase 
AsuE3 371 LimB (Q9EUT9.1) 4-hydroxyprotoasukamycin epoxidase 
AsuD1 531 NovL (AAF67505.1) Amide synthase 
AsuD2 409 MoeC4 (ABJ90148.1) 2-oxoamine synthase 
AsuD3 468 MoeA4 (ABJ90146.1) 5-aminolevulinate CoA ligase 
AsuM1 512 EmrB (YP_001507963.1) Asukamycin exporter 
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bypass these difficulties, the λ-Red recombination system has been developed [83-87]. This in 
vivo recombinant system includes three key proteins, Bet, Exo, and Gam, in which Gam 
stabilizes the transformed linear DNA by inhibiting the RecBCD exonuclease, and Bet/Exo 
promote homologous recombination [88]. Taking advantage of the innate merit of the two shared 
DNA segments of 2B9 and 10D6, the pOJ446 vector and the overlapping 1.8 kb inserts region, 
we further simplified the established λ-RED recombination system by skipping the conventional 
PCR cloning and multiple “stitching” processes, and assembled two cosmids in a single step [84-
86, 89] (Fig. 2.2). 2B9 and 10D6 were linearized by the unique cut restriction enzymes SpeI and 
XbaI, respectively. The linearized cosmids are unable to replicate, while the circular recombinant 
clones resulted from two cosmids will propagate and form colonies under the apramycin 
antibiotic selection. The resulting cosmid, pART1361, was introduced into the S. lividans K4-
114 by conjugation from the E. coli strain. 
Carrying the pART1361, the S. lividans transformant produced the brightly yellowish 
metabolites, which displayed an inhibitory effect against Staphylococcus aureus. HPLC analysis 
detected a group of compounds with an identical UV absorption spectrum and the similar solvent 
mobility as the asukamycin metabolites A1-A7 observed in S. nodosus subsp. asukaensis (Fig. 
2.3). The production of asukamycin and congeners A1-A7 were further confirmed by a high-
resolution LC-MS. In the meantime, the ω-cyclohexyl fatty acids were also detected at 7.8% in 
the S. lividans K4-114 by GC-MS. Notably, the productivity of asukamycin was more stable and 
persistent in S. lividans K4-114 in comparison with its natural host S. nodosus subsp. nodosus, 
possibly due to the imposed apramycin antibiotic selection. 
 In pART1361, located on one end of the insertion were many ORFs related to the 
primary metabolic functions of Streptomcyes species but unlikely involved in the asukamycin 





Figure 2.2 Assembly of two cosmids with overlapping inserts. a, cosmids 2B9 and 10D6 were 
linearized by SpeI and XbaI, respectively. Homologous recombination occurred at two 
overlapping insert and vector regions, indicated by heavy lines. b, the restriction map of 2B9, 
10D6 and pART1361. The inserts are shown with solid lines. The EcoRI fragment sizes are 




Figure 2.3 HPLC analysis of the S. nodosus WT and the S. lividans K4-114 transformants. 
Twenty μL of crude culture extract of the S. lividans K4-114/pART1391 (a), the S. lividans K4-
114/pART1361 (b), the control S. lividans K4-114/pOJ446 (c), and the S. nodosus subsp. 
asukaensis wild type strain (e). The arrows identify the peaks of asukamycin A1 and related 
metabolites, A2-A5, B1-B4. The x axis indicates the time (min); y axis indicates the absorbance 
abundance (mAu). 
 
by replacing it with the spectinomycin resistance gene to give a pART1391. The HPLC, high-
resolution MS, and bioassay further supported that S. lividans K4-114/pART1391 was fully 
capable of producing asukamycin A1 and its congeners A2-A7. These expression results indicate 
that the cloned 36 asu genes in pART1391 are sufficient for the asukamycin production. 
Disscussion 
The chemical structure of asukamycin features two triene polyketide chains locked on a 
3,4-AHBA-originated mC7N core. The lower chain ends with a C5N structural moiety, while the 
upper one starts with a cyclohexane head group. From the sequence analysis, four major groups 
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Figure 2.4 Construction of pART1391. a, spectinomycin resistance gene cassette (spec) was 
PCR amplified from pIJ778 using primers AsuRED-4 and -6. b, the λ-RED based recombination 
was conducted to replace the 25.4 kb insert region of pART1361 with a spec cassette to create 
pART1391. The predicted EcoRI digestion fragments are indicated (kb).c, comparison of the 
EcoRI digestion pattern by DNA gel electrophoresis. Note: Lane pART1381 indicates another 
pART1361 derived cosmid clone which is not related to this study.  
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of the asu genes were proposed to be involved in the structural assembly, including the asuA for 
the biosynthesis and activation of 3,4-AHBA, the precursor of the mC7N core, the asuB for the 
conversion of shikimate to form CHC-CoA, the asuD for the C5N formation, and the asuC group 
for the lower and upper polyketide chain assembly (Fig. 2.1). Besides, the sequenced genomic 
region also covers the putative regulatory genes and an exporter coding gene. The identification 
and the subsequent functional expression of the asu cluster provided a platform for the further 
investigation of these biosynthetic genes.   
Heterologous expression of the entire gene cluster is not only a strategy to confirm the 
putative biosynthetic genes, but also an ideal approach to delineate the boundaries, justify the 
sufficiency, and set a stage for engineering of the targeted gene cluster. However, the frequently 
encountered difficulty is that the intact cluster is not accommodated by one clone from the 
genomic library. For example, cosmid 2B9 and 10D6, together but not one of the two, 
encompasses all the asu genes. To add or trim large genomic DNA regions on a cosmid clone, 
the λ-Red recombination system has been well developed due to the simplicity and high fidelity 
compared with the conventional molecular cloning [83-87]. Recently, Bachmann group 
developed a method to combine two overlapping cosmids, which required three times of λ 
recombinations and a single unique restriction site in the overlap region [85]. Besides, a 
redundant DNA “scar” sequence was also added in the resulting cosmid. 
In this study, taking advantage of the innate merit of the two shared DNA segments, the 
vector and the overlapping inserts region, we further simplified this system by skipping the 
conventional PCR cloning and multiple “stitching” processes, and assembled two cosmids in a 
single step (Fig. 2.2). The target cosmids can be linearized by the restriction enzyme digestion, 
as a majority of commercial cosmid vectors carry multiple rare cut restriction sites such as XbaI 
and SpeI on the pOJ446. The linearized cosmids are unable to replicate, while the circular 
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recombinant clones resulted from two cosmids will propagate and form colonies under the 
antibiotic selection. This straight-forward recombination approach is particularly useful to 
examine the competence of the cloned genes, and provide a convenient platform for the further 
gene manipulations. In this study, the productivity of asukamycin was found more consistant in 
the S. lividans K4-114 introduced with the recombinant pART1361 than its natural producer S. 
nodosus subsp. asukaensis, possibly due to the antibiotic selection pressure. As to be mentioned 
in later chapters, a reliable yield of the novel intermediate 4-hydroxylprotoasukamycin D1 was 
also detected in the S. lividans K4-114 carrying the pART1361E3, which was further generated 
from pART1361 based on the straight-forward λ-Red PCR strategy by replacing the asuE3 with 
a spectinomycin resistance gene.
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Feeding experiments demonstrated that the mC7N core structure is resulted from the 
precursor 3,4-AHBA in the asukamycin biosynthesis [19, 58]. Two genes in the cloned asu 
cluster, asuA1 and asuA3, are closely related to the griH and griI involved in the grixazone 
biosynthesis in Streptomyces griseus [59]. GriI catalyzes an aldol condensation using L-
aspartate-4-semialdehyde (ASA) and dihydroxyacetone phosphate (DHAP) to form a putative 
intermediate 2-amino-4,5-dihydroxy-6-one-heptanoate-7-phosphate, which could be further 
converted to 3,4-AHBA by GriH, an intra-molecular cyclase. Notably, the griH and griI locate 
side-by-side in the genome of S. griseus, while the asuA1 and asuA3 separate apart from each 
other by eight additional ORFs. To confirm their roles in 3,4-AHBA formation of asukamycin, 
we constructed two mutants by disrupting the corresponding asuA1 and asuA3. Neither 3,4-
AHBA nor asukamycin were detected in these mutants (Fig. 3.1). The asukamycin production 
can be further restored with the addition of 3,4-AHBA in both mutant cultures. Moreover, LC-
MS analysis revealed a small amount of the novel products, E1 and E3/E4, which possess a C5N 
moiety amide-linked with the triene upper chains corresponding to A1 and A3/A4, respectively 
(Fig. 3.2). 
Activation of 3,4-AHBA 
Previous feeding studies indicated that the lower polyketide chain assembly begins on 
3,4-AHBA as a starter building block [60]. According to several polyketide/polypeptide 
biosynthetic systems that employ AMP-linked aroyl starters [90-92], 3,4-AHBA is presumably 
activated via adenylation and then tethered to a specific aroyl carrier protein (ArCP) for the 





Figure 3.1 HPLC analysis of the asuA1 and asuA3 mutants. Twenty μL of crude culture 
extract of the asuA1 mutant (a), the asuA3 mutant (b), the asuA1 mutant supplemented with 3,4-
AHBA (c), the asuA3 mutant supplemented with 3,4-AHBA (d), and the S. nodosus subsp. 
asukaensis wild type strain (e). The arrows identify the peaks of asukamycin A1 and related 




Figure 3.2 Proposed structures of E1 and E3/E4. The exact mass of E1 is 301.1670 
(calculated for C18H23NO3, 301.1678; mass error, 3.30 ppm) with a fragment 189.1272 
(calculated for C13H17O, 189.1279). The exact mass of E3/E4 is 275.1501 (calculated for 
C16H21NO3, 275.1521; mass error, 7.58 ppm) with a fragment 163.1105 (calculated for C11H15O, 
163.1123). 
 
homologous to the coding gene for the actinomycin synthetase I (ACMS I), which initiates the 
actinomycin formation in Streptomyces chrysomallus by activating 4-methyl-3-
hydroxyanthranilate (4-MHA) in the presence of ATP [90]. To examine the function of AsuA2, 
we constructed a mutant by replacing asuA2 with an apramycin resistant cassette. The asuA2 
mutant failed to produce asukamycins, but accumulated 3,4-AHBA through HPLC analysis (Fig. 
3.3). The detected 3,4-AHBA also could complement the asukamycin production of the 3,4-
AHBA-deficient asuA1 mutant upon co-culturing (Fig. 3.4). Located seven ORFs upstream of 
the asuA2, the asuC11 and asuC12 both belong to the gene family coding for the acyl carrier 
protein (ACP). AsuC12 is distinctly related to AcmACP, a specific ArCP of the actinomycin 
pathway, which escorts the priming molecule 4-MHA-AMP to the peptide synthase AcmII for 
chain initiation [90]. The mutant in which both asuC11 and asuC12 were truncated showed a 
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similar phenotype as the asuA2 mutant, i.e., 3,4-AHBA accumulation and no asukamycin 




Figure 3.3 HPLC detection of 3,4-AHBA in the asuA2, asuC11C12, and asuC13 mutants. 
200 μL of crude culture extract from the aqueous layer of the asuA2 mutant (a), the asuC13 
mutant (b), the asuC11C12 mutant supplemented (c), and the control group, asuA1 mutant (d). 
The dash line identifies the peaks of 3,4-AHBA. The x axis indicates the time (min); y axis 




Figure 3.4 HPLC analysis of the asuA2, asuC11C12, and asuC13 mutants. Twenty μL of 
crude culture extract of the asuA2 mutant (a), the asuC13 mutant (b), the asuC11C12 mutant (c), 
the S. nodosus subsp. asukaensis wild type strain (g), and 100 μL crude co-culture extract of the 
asuA2 and the asuA1 mutant (d), the asuC13 and the asuA1 mutant (e), the asuC11C12 and the 
asuA1 mutant (f).   
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Assembly of Lower Polyketide Chain 
Positioned next to the asuC12, the asuC13 has strong similarity to a group of genes 
encoding for the type II iterative fatty acid/polyketide synthases (FAS/PKS) [93, 94]. Besides 






 catalytic triad, AsuC13 also holds several conservative 
hydrophobic residues, which have been depicted to form a pocket to accommodate the ongoing 
acyl intermediate in the bacterial fatty acid synthases [95-97]. As the constructed asuC13 mutant 
failed to produce asukamycins and accumulated 3,4-AHBA, similar to the asuA2 and 
asuC11C12 mutants, AsuC13 was confirmed to be a KSI/II polyketide synthase  involved in the 
lower polyketide chain assembly (Fig. 3.3 and 3.4). Notably, trace amounts of E1 and E3/E4 
were also found in this mutant culture as observed in the asuA1 and asuA3 mutants. Immediately 
downstream of asuC13, the asuC14 encodes a protein homologous to AsuC13, except for a 
truncated N-terminus and lacking the characteristic Cys-His-His catalytic triad. Coincidently, 
this uncommon asuC13/asuC14 gene pair, in which an intact polyketide synthase gene 
accompanies a partially truncated partner, is also present in the uncharacterized gene clusters 
from the genomic sequencing projects of Streptomyces hygroscopicus (ZP_05513707-8) and 
Salinispora arenicola (YP_001535964-5 and YP_001537504-5). So far, the AsuC14 function 
remains unknown.  
Two additional reactions, a β-keto reduction and a dehydration, are required in the 
formation of the lower triene polyketide. Sequence analysis revealed that only one set of genes, 
the asuC7-C9, could fulfill these anticipated functions in the cloned asu cluster. AsuC7 displays 
a high homology to several polyketide ketoreductases (KR), including the bacterial FabG 
proteins, the SCO1815 from Streptomyces coelicolor, and the MabA from Mycobacterium 
tuberculosis [98, 99]. Two putative dehydratase genes asuC8 and asuC9 were found downstream 






and is closely related to the HadB, which forms a heterodimer with either the HadA or HadC to 
act on the compilation of the long chain mycolic acids in M. tuberculosis H37Rv [100-103]. 
Coincidently, AsuC8 is highly related to both HadA and HadC. As asuC7 and asuC8,C9 are the 
only genes in the cluster which could be involved in β-keto reduction and dehydration of the 
polyketide, we suggest that they operate in the assembly of the lower as well as the upper trans 
triene chains (to be discussed in the following chapter).  
Discussion 
3,4-AHBA is a common precursor for several natural products, such as manumycin A-C, 
grixazones, and  4-hydroxy-3-nitrosobenzamide in the corresponding Streptomyces parvulus, 
Streptomyces griseus, and Streptomyces murayamaensis. These cloned biosynthetic genes, asuA3 
and asuA1, could serve as probes to fish other gene clusters for these 3,4-AHBA related 
metabolites. By using their homologous gene probes, griI and griH, Ohnishi and co-workers 
recently identified the 4-hydroxy-3-nitrosobenzamide biosynthetic gene cluster [104]. Moreover, 
the genome mining could further extend to a long list of asuA3 and asuA1 homologs deposited in 
GenBank to explore the 3,4-AHBA related natural products.  
The results indicate that 3,4-AHBA is activated by AsuA2 to form an acyl-AMP, 
subsequently loaded onto the aroyl carrier protein AsuC12 to initiate the lower polyketide 
assembly (Fig. 3.5). Construction of the lower polyketide chain likely requires a set of type II 
polyketide synthetic enzymes including the KSI/II AsuC13,C14, the KR AsuC7 and the DH 
AsuC8,C9, based on the sequencing and mutagenic analysis (Fig. 3.5). AsuC13 and AsuC14 are 
most likely responsible for the initiation and two further rounds of polyketide chain extensions, 
as the lower chain biosynthesis was abolished in the asuC13 mutant. The presence of asuC14 
might not be coincidental. AsuC13 and AsuC14 could function together to constrain the growing 
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triene structures and control the polyketide chain length. Further studies on other manumycin 
biosynthetic genes should provide more clues on the function of asuC14. Since the asuC11 is 
potentially organized in the same transcription unit with the asuC12-C14, AsuC11 ACP could be 
involved in the second and the third rounds of lower chain polyketide extensions.  
Interestingly, governing the lower chain biosynthesis, asuA1-A3 and asuC11-C14 are 
discretely located, while their homologs in S. hygroscopicus, ZP_05513702-8, are organized in a 
seven-gene cluster, and likely function in a sequential order, suggesting that asukamycin 
biosynthesis has evolved through multiple horizontal gene transfer events and possibly an 





Figure 3.5 Proposed biosynthetic pathway of asukamycin lower chain.  
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Unlike other manumycins, the formation of the asukamycin upper polyketide chain starts 
with cyclohexylcarbonyl-CoA (CHC-CoA), which is derived from the primary metabolite, 
shikimic acid [60]. Four clustered genes, asuB1-B4, are homologous to two independent gene 
sets, ansJKLM/chcA from the ansatrienin producer S. collinus and plmJKLM/chcA from the 
phoslactomycin producer Streptomyces sp. HK-803, which are involved in CHC-CoA 
biosynthesis [62, 105]. All these CHC-CoA biosynthetic genes are organized in the same order in 
these three strains. Notably, AsuB1 and PlmJK are likely bifunctional proteins which contain an 
N-terminal 5-enolpyruvylshikimate-3-phosphate synthase (EPSP synthase) domain as well as a 
cyclohexanecarboxylate-CoA ligase domain at C-terminus. However, these functional activities 
are carried out by two separated protein products AnsJ and AnsK in S. collinus. Constructed by 
gene disruption, the asuB1 mutant failed to produce asukamycin, but levels of the previously 
identified asukamycin congeners A2-A7 were increased three-fold compared with those of the 
wild type strain (Fig. 4.1). LC-MS analysis further identified three new compounds A8, B8 and 
C8 (Fig. 4.2 and 4.3). The NMR analysis of B8 revealed a B1-like structure except that the upper 
polyketide chain was replaced by an acetyl group (Table 4.1). Based on the molecular weight, 
compounds C8 and A8 are likely the proto- and type I-form of B8, respectively. These products 
probably resulted from an increasingly buildup of the 3,4-AHBA-lower chain-ACP intermediate. 
Besides, GC-MS analysis revealed that the cellular level of ω-cyclohexyl fatty acids were at 
7.8% in the S. lividans K4-114/pART1391 but not in the control strain carrying an empty vetor, 









Figure 4.1 HPLC analysis of the asuB1, asuC3C4 mutants, and the S. nodosus wild type 
strain. Twenty μL of crude culture extract of the asuB1 mutant (a), the asuC3C4 mutant (b), and 
the S. nodosus subsp. asukaensis wild type strain (c). The arrows identify the peaks of 
asukamycin A1 and related metabolites, A2-A5, B1-B4. The y axis indicates the absorbance 




Figure 4.2 HPLC detection of A8, B8, and C8 in the asuB1 and asuC2 mutants. Twenty μL 
of crude culture extract of the asuB1 mutant (a) and the asuC2 mutant (b). An old culture of 
asuC2 mutant was shown in panel c. The dash lines identify the peaks of A8, B8, and C8. The y 
axis indicates the absorbance abundance (mAu). 
 
 
Figure 4.3 Molecular structures of A8, B8, and C8.   
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C-NMR of B8. 
Position δC (ppm) δH (ppm) 
1 192.6 -- 
2 130.8 -- 
3 129.6 7.27 (d, J=7.8) 
4 73.0 -- 
5 71.3 3.85 (m) 
6ax 40.1 2.71 (dd, J=16.8, 3.2) 
6eq  2.59 (dd, J=16.5, 6.07) 
7 138.4 6.12 (d, J=15.2) 
8 131.5 6.43 (dd, J=14.9, 11.5) 
9 138.8 6.67 (dd, J=15.1, 10.9) 
10 129.5 6.47 (dd, J=15.2, 11.0) 
11 140.3 7.12 (dd, J=15.0, 11.5) 
12 124.5 6.38 (d, J=15.0) 
13 165.0 -- 
1’ 169.5 -- 
2’ 23.9 1.90 (s) 
1’’  -- 
2’’  -- 
3’’  -- 
4’’   
5’’   
NH-14  8.91 (s) 






H-NMR signals for C1’’- C5’’ are undetectable in DMSO-d
6





Assembly of the Upper Polyketide Chain 
To initiate fatty acid or polyketide biosynthesis, acyl-CoA starters are recruited and 
condensed with a (methyl)-malonyl-ACP by the action of fatty acid synthases FabH or the 
polyketide synthases III (KSIII). This is distinct from the action of KSI/II, joining two ACP-
bound acyl substrates in the subsequent chain extensions in many microorganisms [93, 94]. The 
adjacent asuC3 and asuC4 are homologous to numerous genes encoding bacterial FabHs and 
KSIIIs including the zhuH of Streptomyces. sp. R1128 [106, 107]. Both AsuC3 and AsuC4 
feature a putative CoA binding site and a conserved Cys-His-Asn catalytic triad, which is crucial 
for the nucleophilic acyl substitution. As AsuC3 and AsuC4 are highly similar to each other, we 
assume that they might act together as a heterodimer to condense the CHC-CoA and malonyl-
ACP to give a 3-cyclohexyl-3-oxopropanoyl-ACP intermediate for the downstream polyketide 
chain assembly. Interestingly, a double mutation of asuC3 and asuC4 did not completely 
eliminate the asukamycin production. The asuC3C4 mutant retained 0.9% asukamycin A1 and 
30.0% congeners A2-A7 relative to the wild type strain yield (Fig. 4.1), possibly due to a 
functional complementation by the cellular FabH involved in the fatty acid biosynthesis. AsuC5, 
presumably organized in the same transcription unit with asuC3,C4, is a zhuG homolog [108]. 
As ZhuG acts together with ZhuH to initiate the assembly of the antitumor polyketide R1128 
[108], AsuC5 may play a crucial role in the beginning round of asukamycin upper chain 
assembly. So far, the KSI/II gene(s) required for the second and third round extensions of the 
upper chain remain to be identified. 
Attachment of the Upper Polyketide Chain  
Asukamycin contains two amide bonds, the linkage between the upper chain and the 
mC7N core, and the bridge tethering the C5N moiety to the lower polyketide chain. Coincidently, 
two putative amide synthase genes, the asuD1 and asuC2, were detected in the cloned cluster. 
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Sited together with the asuD2 and asuD3 and possibly sharing the same transcription unit, the 
asuD1 is likely involved in the C5N moiety biosynthesis (see the following chapter), while the 
asuC2 was detected immediately upstream of the asuC3-C5, presumably organized in the same 
transcription unit. AsuC2 is homologous to the family of N-acyltransferases, which contains the 
arylamine N-acetyltransferase (NAT 1), Asm9, and RifF from the corresponding Mesorhizobium 
loti MAFF303099, Actinosynnema pretiosum subsp. auranticum, and Amycolatopsis 
mediterranei S699 [109-112]. An asuC2 disrupted mutant was constructed to confirm its 
involvement in the attachment of the upper chain to the 3-amino group of the 3,4-AHBA primed 
polyketide intermediate. The production of asukamycins A1-A7 was completely blocked in the 
asuC2 mutant. Instead, the N-acetylated compounds A8, B8 and C8 were accumulated, as 
observed in the asuB1 mutant (Fig. 4.2 and 4.3). In view of the functional deficiency of asuC2, 
these shunt products presumably resulted from the action of a cellular arylamine N-
acetyltransferase, commonly found to detoxify arylamine or arylhydroxylamine metabolites 
[113, 114].  
Discussion   
The asuB gene set likely governs the conversion of shikimic acid to give CHC-CoA, the 
polyketide starter of asukamycin upper chain, as their homologous genes in S. collinus, 
ansJKLM/chcA, were confirmed to be essential for the same conversion by mutation 
experiments. Despite that, only the AsuB3 homolog, ChcA, has been proved to catalyze three 
independent reactions in vitro, including reductions of 1-cyclohexenylcarbonyl CoA, 5-hydroxy-
1-cyclohexenylcarbonyl CoA, and 4,5-dihydroxy-1,5-cyclohexadienylcarbonyl CoA (Fig. 4.4) 
[115]. In these steps, ChcA reduces α, β-double bonds of either an enoyl or dienoyl CoA 
substrate with the same stereochemistry pattern: anti fashion with addition of solvent hydrogen 
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to the si face of the α-carbon. Besides, the mutation and in vitro studies demonstrated that the 




 enoyl CoA isomerase in Streptomyces, is required for 
the perultimate step in the CHC-CoA formation. 
Sequence analysis indicated that AsuB1 is a bifunctional protein, where the C-terminal 
domain is similar to a number of acyl-CoA ligases, implying the role of incorporating a CoA to 
the carboxyl group of shikimate [116]. The N-terminal (1-424aa) domain of AsuB1 shows a 
relatively weak similarity with the well-characterized EPSP synthase involved in the conversion 
of shikimate to form chorismate. Rather than a real EPSP synthase functioning to conjugate PEP 
to the shikimate 3-phosphate, AsuB1 may play a role in the 1,4-anti elimination of shikimate or 
shikimate 3-phosphate (Fig. 4.4) [62, 116]. Although AsuB2 and AsuB4 are homologous to an 
acyl-CoA dehydrogenases and an oxidoreductase, respectively, the exact function of these two 
enzymes remain to be determined. 
 
 
Figure 4.4 Proposed biosynthesis pathway of CHC-CoA in S. nodosus subsp. asukaensis. 
Related homologous enzymes are indicated in brackets. The question marks indicate the 
unverified roles of the essential enzymes. 
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For the assembly of asukamycin upper polyketide, AsuC3,C4 likely initiate the 
condensation between CHC-CoA and malonyl-ACP, resembling the bacterial FabH and other 
KSIIIs, which are directly primed with an acyl-CoA (Fig. 4.5). In the asuC3,C4 mutant most 
asukamycin A1 production was abolished, and levels of the congeners A2-A7 were also reduced 
compared to the wild-type. This reflects a possible involvement of the cellular fatty acid synthase 
FabH, which displays a substrate preference distinct from AsuC3,C4, priming preferentially with 




Figure 4.5 Comparison of biosynthetic pathways of asukamycin upper chain, R1128A, and 
fatty acids. The ACPs are in capsules. Enzymes dedicated in the first condensation are shown in 
blue; the ones responsible for the iterative extensions are indicated in red. 
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The involvement of AsuC3,C4 in the second and third chain elongations is less likely, as 
FabH catalyzes only the first condensation step and passes the resulting 3-ketoacyl-ACP directly 
to another enzyme complex for further reductions and chain elongations. Given that E1 and 
E3/E4 were found in the asuC13 mutant, the only recognized KSI/II gene pair, asuC13,C14, 
may not play a crucial role in the upper chain assembly, although both the upper and lower 
polyketide chains of asukamycin share an identical triene structure. It seems that an unidentified 
polyketide KSI/II is required to act together with the KR AsuC7 and DH AsuC8,C9 to carry out 
the upper triene polyketide extension. We also cannot rule out the involvement of a cellular 
FabB/F-like fatty acid synthase, as the successful heterologous expression in S. lividans implies 
that a common KSI/II or FASI/II can fulfill the functional role of this unidentified β-keto 
condensation enzyme. 
The formation of A1-A4 only differs at the priming step of the upper polyketide chain. 
Instead of CHC-CoA starter, A2-A4 employ the branched acyl-CoA thioesters, the 
corresponding 2-methylpropionyl-CoA, 2- and 3-methylbutanoyl-CoA, which are predominantly 
used for fatty acid synthesis in Streptomyces (Fig. 4.6) [10]. These starters, 2-methylpropionyl-
CoA, 2- and 3-methylbutanoyl-CoA, are derived from the corresponding branched-chain amino 
acids, valine, leucine, and isoleucine. In the asuB1 mutant, the absence of CHC-CoA abolished 
the entire A1 production and redirected the biosynthetic flux to A2-A4. Since A2-A4 formation 
was ten-fold higher in this mutant than in the asuC3,C4 mutant, the majority of A2-A4 upper 
polyketide initiation is likely performed by the KSIII AsuC3,C4, and only a minor fraction of 
A2-A4 production in the asuB1 mutant as well as the wild type strain is contributed by the FabH 
activity. The relatively small amount of A5-A7 production could result from an action of the 
primary FAS complex to give 4-methylpentanoyl-, 5- and 4-methylhexanoyl-ACP intermediates. 
These ACP-tethered thioesters could be directly recruited by an unidentified KSI/II or FASI/II to 
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perform three additional elongations and introduce the characteristic triene in analogy with the 
A1-A4 upper chain biosynthesis. These observations are in agreement with the involvement of 
FabH and suggest a physiological cross-talk between polyketide and fatty acid biosynthesis. 
 
Figure 4.6 Proposed upper chain assemblies of the asukamycin congeners (A2-A7). 
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CHAPTER FIVE:  
 
ASUKAMYCIN C5N MOIETY FORMATION 
53 
Results 
Three gene sets have been studied for the C5N moiety formation, including the ones for 
moenomycin A, ECO-02301, and ECO-0501 from the corresponding Streptomyces ghanaensis, 
Streptomyces aizunensis NRRL B-11277, and Amycolatopsis orientalis [69, 70, 117]. Each 
carries three highly conserved genes encoding for a 5-aminolevulinate (5-ALA) synthase-like 
enzyme, an acyl-CoA ligase, and an amide synthase. To the asu cluster, three adjacent genes, 
asuD1, asuD2, and asuD3, were found and appeared to share a common transcription unit (Fig. 
2.1). 
Previously identified as HemA-AsuA, AsuD2 belongs to the family of pyridoxal 
phosphate (PLP)-dependent 2-oxoamine synthases, including 5-ALA synthase, FUM8, L-serine 
palmitoyltransferase (SPT) and 8-amino-7-oxononanoate synthase (AONS), which catalyze the 
decarboxylative condensation between an amino acid and an acyl-CoA in the assembly of 
corresponding 5-ALA, fumonisin, ceramide-sphingolipid, and biotin [21, 118-121]. The gene 
disrupted asuD2 mutant failed to produce the asukamycin products, nevertheless the asukamycin 
productivity was recovered by reintroducing an expression plasmid pALS4 carrying the asuD2 
[21]. Unexpectedly, the asukamycin production could not be complemented by the existing C5 
pathway, or recovered by adding exogenous 5-ALA to the asuD2 mutant culture, which implied 
that AsuD2 functions differently from the well-known 5-ALA synthase in the Shemin pathway 
to produce 5-ALA in many organisms (Fig. 1.7).  
Despite high overall sequence similarity, AsuD2 possesses a Ser83 instead of a strictly 
invariant Thr83 of the 5-ALA synthase subgroup (Fig. 5.1). To examine the essentiality of this 
residue for the enzymatic activity, Petricek group constructed a pALS4-S83T with a S83T 
replacement in asuD2, which failed to restore the asukamycin production in the asuD2 mutant 
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(Fig. 5.2). Surprisingly, the pALS4-S83T complemented a 5-ALA-deficient gtr mutant of S. 









 positions are highlighted in red. Sequences of enzymes involved in the C5N moiety 
assembly are boxed. The ruler above indicates positions of amino acid residues relative to 
AsuD2. The enzymes functions/accession number/original strains: AsuD2 
(asukamycin/AAO62615/S. nodosus); Eco-Orf34 (Eco-02301/AAX98209/S. aizunensis); Eco-
Orf16 (Eco-0501/ABM47017/Amycolatopsis orientalis); MoeC4 (Moenomycin A/ABJ90148/S. 
ghanaensis ATCC 14672); MoeA5 (Moenomycin A/ ABJ90153/S. ghanaensis ATCC 14672); 
AONS (8-amino-7-oxononanoate/pdb1BS0/E. coli); 5-ALAS-H (5-ALA/NP_000679/Homo 
sapiens); 5-ALAS-Y (5-ALA/ NP_010518/Saccharomyces cerevisiae); 5-ALAS-A (5-
ALA/NP_355550/Agrobacterium tumefaciens); 5-ALAS-R (5-ALA/CAA37857/Rhodobacter 
capsulatus)  
 
AsuD3, an acyl-CoA ligase, is proposed to act on the C5N ring formation, since 
disruption of the homologous moeA4 in Streptomyces ghanaensis led to accumulation of a 
moenomycin A analog lacking the C5N moiety [117]. Located immediately upstream of asuD2, 
the asuD1 is closely related to a group of amide synthase genes, including the simL and novL for 
the biosynthesis of simocyclinones and novobiocin in Streptomyces antibioticus Tü 6040 and 








Figure 5.2 TLC analysis and bioassay of the AsuD1-D3 enzymes. a, and c, chromatograms 
visualized under UV 254 nm. b, the same TLC plate was further overlaid with Bacillus subtilis 
mixed with nutrient agar and incubated overnight at 37°C. The red arrow shows the newly 
formed product 2880-II. Lane 1, the wild type strain; Lane 2, the asuD2 mutant; Lane 3, the 
asuD2 mutant/pALS4; Lane 4, the asuD2 mutant/pALS4-S83T; Lane 5, standard asukamycin 
(10 μg); Lane 6, S. lividans/pAS9A1; Lane 7,8, S. lividans/pAS9A1 supplemented with ferulic 
acid (2.5 mg/ml); Lane 9, standard ferulic acid (10 μg). d, the conversion of ferulic acid to give 
2880-II. *Communicated with Petricek group. 
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All the asuD1, D2 and D3 mutants failed to produce asukamycin, but accumulated a new 
set of metabolites, A1a-A5a, which were shown closely related to the corresponding A1-A5 but 
with 95 Dalton less molecular weights, suggesting that the amide-linked C5N moiety of A1-A5 
was replaced by a free carboxyl group in A1a-A5a (Fig. 5.3). The corresponding type II 
compounds, B1a-B5a, were also present in all three mutants. To confirm the asuD1-D3 
involvement in the C5N moiety formation, the asuD1-D3 operon was further cloned under the 
control of the constitutive ermE* promoter and expressed in S. lividans. A novel brown 
metabolite was detected, but further attempts to characterize the compound have failed so far. 
Feeding ferulic acid to this strain, a new compound was obtained with a molecular weight of 
290.097 (Fig. 5.2). MALDI-TOF MS-MS analysis of the TLC purified compound revealed an 
identical fragmentation pattern as the reported compound 2-(feruloylamino)-3-hydroxypent-2-
enolone (2880-II) which possesses a C5N moiety connected to the carboxyl group of ferulic acid 
[125]. 2880-II could not be formed if any one of the asuD1, asuD2 or asuD3 was omitted from 
the expression cassette. 
Discussion 
The asuD1, D2, and D3 mutants revealed an identical set of accumulated products A1a-
A5a, indicting their necessity for the assembly and attachment of the last piece of asukamycin 
building blocks, the C5N moiety. The sufficiency of AsuD1-D3 for this process was also 
supported by the functional expression to convert ferulic acid into 2880-II in S. lividans. As a 
member of the 2-oxoamine synthases, the AsuD2 displays a high homology to the 5-ALA 
synthase, which is a dedicated enzyme in charge of the condensation of glycine and succinyl-
CoA to form the 5-ALA, a primary metabolite and the possible precursor for the C5N moiety [21, 




Figure 5.3 HPLC analysis of the asuD1, asuD2, and asuD3 mutants. Twenty μL of crude 
culture extract of the asuD1 mutant (a), the asuD2 mutant (b), and the asuD3 mutant (c). The 
arrows identify the peaks of A1a-A5a, B1a-B4a. The y axis indicates the absorbance abundance 
(mAu). Structures of A1a-A5a, B1a-B4a are shown in (d). 
58 
 complement the functional activities of each other [21], AsuD2 could represent a new subfamily 
of enzymes that deviate from a valid 5-ALA synthase in the evolution. As the 2-oxoamine 
synthases catalyze the condensation between the Cα of an amino acid and a CoA thioester, we 
suggest that AsuD2 could also perform the intra molecular C-C bond formation between the Cα 
and Cε to give a C5N ring structure. A nascent PLP-bound 5-ALA, or possibly the pre-
decarboxylated intermediate, 2-amino-3-oxoadipate, could be carboxyl-activated by the action of 
the CoA ligase AsuD3, followed by cyclization catalyzed by AsuD2 (Fig. 5.4). The dual role of 
AsuD2 is also supported by the results of the heterologous expression of asuD1-D3 to produce 
the C5N unit in the absence of any other candidate cyclase gene in S. lividans. The amide 
synthase AsuD1 is responsible for the attachment of the C5N unit to the carboxy-terminus of the 
lower chain. As all the assumed intermediates in this process are relatively unstable [20], AsuD1, 
D2 and D3 might work together to secure the formation of protoasukamycin. 
Similar to other 2-oxoamine synthases, such as FUM8, SPT, and AONS that employ the 
amino acids containing bulky side-chain rather than glycine, AsuD2 bears a Ser83 in the position 
of the conserved Thr83 of 5-ALA synthase (Fig. 5.1). The distinct role of Ser83 in C5N moiety 
formation was confirmed by expression of AsuD2-S83T, which failed to complement the asuD2 
mutant but restored the ability of 5-ALA formation in the gtr mutant of S. coelicolor. This point 
mutated AsuD2-S83T resembles an authentic 5-ALA synthase, which emerged as a serendipitous 
Shemin route to provide sufficient 5-ALA for the growth of gtr mutant. Revealed by the crystal 
structure of ALASRc from Rhodobacter capsulatus, the side-chain methyl group of Thr83 
interacts with the Cα atom of the PLP-glycine intermediate (3.9 Å) at the active site [118]. In the 
presence of this methyl group of Thr83, amino acids other than glycine could not properly 
interact with the succinyl-CoA stubstrate, as the bulky side chain will confine the substrate 
binding capacity. On contrary, the Ser83 containing enzymes, including FUM8, SPT, and 
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AONS, are able to accommodate larger amino acids than glycine, such as alanine and serine. 
This not only provides another evidence for the cyclization function of AsuD2 proposed 
previously, but also implies the S83T mutation confines the substrate binding pocket, which 




Figure 5.4 The proposed C5N moiety biosynthetic pathway and the coexisting C5 pathway. 
The dashed arrow indicates the serendipitous Shemin pathway triggered by AsuD2-S83T 




CHAPTER SIX:  
 
POST-ASSEMBLY OXYGENATION OF PROTOASUKAMYCIN 
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Results 
Growing S. parvulus Tü64 under an 
18
O2 atmosphere has demonstrated that the hydroxyl 
and the epoxide oxygens at the C4 and C5-C6 positions of manumycin A originate from 
molecular oxygen, through either a dioxygenase mechanism or a two-step process (Fig. 1.8) [20, 
76]. There was no closely related dioxygenase gene detected along the cloned cluster except that 
three distantly located genes, the asuE1, asuE2 and asuE3, are likely involved in the oxygenation 
reaction(s). AsuE1 is homologous to the p-hydroxybenzoate hydroxylase (PHBH), which 
converts p-hydroxybenzoate to form 3,4-dihydroxybenzoate in Pseudomonas aeruginosa (Fig. 
6.1) [126]. PHBH is also a bifunctional enzyme which revitalizes an oxidized FADox to FADred 
in the presence of NAD(P)H and resume a next round of hydroxylation [127, 128]. Instead to 
produce asukamycin, the asuE1 mutant was found to accumulate protoasukamycin C1 and a 
series of protoasukamycin related congeners C2-C5 in the fermentation cultural broth based on 
LC-MS analysis (Fig. 6.2).  
 
 
Figure 6.1 Reactions catalyzed by PHBD, PheA1/A2, and LimB.  
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AsuE2 is a homolog of the flavin reductase PheA2, which makes a FADred available to its 
hydroxylase partner PheA1 in the phenol hydroxylation in Bacillus thermoglucosidasius A7 (Fig. 
6.1) [129]. Interestingly, a major amount of the protoasukamycin products C1-C5 and a 
considerably lower yield of asukamycin A1 were detected in the asuE2 mutant (Fig. 6.2, 6.3). 
This result was rather unexpected and implied that the presence of the AsuE2 FAD reductase is 
required to support a full catalytic function of AsuE1, which is distinct to the bifunctional 
activity of PHBH. 
The asuE3 is highly related to the limB, encoding for a limonene 1, 2-monooxygenase, 
which opens the double bond of limonene and introduces an epoxide to form limonene-1, 2-
epoxide in Rhodococcus erythropolis [130]. Neither asukamycin nor its congeners were detected 
in the asuE3 mutant culture. Instead, a significant amount of a bright yellowish compound was 
accumulated and revealed a distinct retention time but with a similar UV absorption pattern of 
asukamycin A1 by HPLC analysis (Fig. 6.2). A high resolution MS analysis suggested that one 




C-, HMBC and HSQC 
NMR analysis of the purified compound pointed out that a signature alkene is positioned at C5 
(152.5 ppm) and C6 (130.6 ppm) to replace the characteristic epoxide group of asukamycin A1 
(Table 6.1). This newly identified compound was assigned as 4-hydroxyprotoasukamycin D1 
(Fig. 6.3). Meanwhile, a group of 4-hydroxyprotoasukamycin related congeners D2-D7 also 
presented in the fermentation culture based on the LC-MS analysis. D1 was fed into the 
fermentation culture of the asuA3 mutant and converted to asukamycin A1, which suggested that 
D1 was indeed an intermediate and was further epoxidized by AsuE3 in the final biosynthetic 






Figure 6.2 HPLC analysis of the asuE1-E3 mutants. Twenty μL of crude culture extract of the 
asuD1 mutant (a), the asuD2 mutant (b), and the asuD3 mutant (c). Feeding asuA3 mutant with 
pure D1 is shown (d). The arrows identify the peaks of A1-A5, B1-B4, C1-C5, D1-D5. The y 
axis indicates the absorbance abundance (mAu).  
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J-heteronuclear carbon-proton shift correlation methods (HSQC and HMBC). 
Position δC (ppm) δH (ppm) C,H-Coupling
a
 
1 180.07 -- 6-H, 0-NH, 5-H, 3-H 
2 140.95 -- -- 
3 124.57 6.21 (d, J=10.1) 0-NH (w) 
4 69.63 -- 7-H, 3-H, 8-H, 5-H (w), 0-NH (w) 
5 152.53 6.93 (dd, J=10.0, 3.1) 6-H, 7-H, 3-H (w) 
6 130.64 7.62 (d, J=2.95) 5-H, 3-H, 7-H, 0-NH 
7 137.64 5.80 (d, J=15.5) 6-H, 5-H, 3-H, 8-H, 9-H 
8 131.12 6.48 (dd, J=14.8, 11.8) 9-H, 10-H 
9 138.97 6.66 (dd, J=14.8, 11.2) 7-H, 8-H, 11-H 
10 129.35 6.53 (dd, J=15.37, 11.31) 8-H, 11-H  
11 141.23 7.07 (dd, J=15.0, 11.6) 10-H, 12-H 
12 123.47 6.46 (d, J=15.2) 11-H, 10-H 
13 164.94 -- 14-NH 
1’ 164.94 -- 0-NH, 2’-H 
2’ 123.85 6.51 (d, J=15.2) 3’-H, 4’-H 
3’ 141.23 7.15 (dd, J=15.0, 11.6) 2’-H, 4’-H, 5’-H 
4’ 128.53 6.30 (dd, J=14.9, 11.7) 3’-H, 2’-H, 6’-H 
5’ 140.59 6.63 (dd, J=15.0, 10.9) 3’-H, 6’-H, 7’-H 
6’ 127.67 6.18 (dd, J=15.2, 10.9) 4’-H, 5’-H 
7’ 144.84 5.90 (dd, J=15.4, 7.0) 5’-H, 9’/13’-H (w) 
8’ 40.46 2.08 (m) 6’-H, 7’-H, 9’/13’-H, 10’/12’-H 
9’,13’ 32.10 1.70 (m), 1.09 (m) 10’/12’-H, 13’/9’-H, 7’-H, 11’-H  
10’,12’ 25.39 1.26 (m), 1.68 (m) 11’-H, 9’/13’-H,  12’/10’-H 
11’ 25.60 1.13 (m), 1.63 (m) 10’/12’-H, 9’/13’-H 
1’’    
2’’ 113.57 --  
3’’    
4’’    
5’’    
NH-14  9.20 (s)  
NH-0’  9.17 (s)  
a.





















Figure 6.3 Structures of C1-C5, D1-D5. 
Discussion 
Both one-step dioxygenase and two-step monooxygenase mechanisms have been 
proposed for the epoxyquinol structure formation of the manumycin compounds [20, 38, 60]. 
The mutagenesis studies supported that the 4-hydroxyl group is introduced to protoasukamycin 
C1 to give a 4-hydroxylprotoasukamycin intermediate D1 through the actions of AsuE1 and 
AsuE2, and AsuE3 further introduces an epoxide to replace the C5,6-double bond of D1 to form 
asukamycin A1 (Fig. 6.4). The C1 hydroxylation is catalyzed by AsuE1, whose full function 
requires the AsuE2 FAD reductase, possibly by using a reductive cofactor NAD(P)H. and the 
FAD reduction by AsuE2, possibly using a reductive cofactor NAD(P)H, is required for a full 
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function of AsuE1. Since the intermediate D1 was not detected in the asuE2 mutant, it is less 
likely that the AsuE3 epoxidation depends on the presence of AsuE2.  
 
Figure 6.4 A comparison of two-step monooxygenase and one-step dioxygenase 
mechanisms for the respective asukamycin and vitamin K oxide biosynthesis. 
 
As AsuE3 acts specifically on the cyclohexa-2,5-dienone moiety but not a phenol like 
structure, the protoasukamycin 4-hydroxylation to offer a constrained C5,6-double bound is 
critical for the epoxidation. Correspondingly, the mmyO, encoding an AsuE3-related epoxidase, 
was also found in the deposited methylenomycin A biosynthetic gene cluster of Streptomyces 
coelicolor A3(2) [131, 132]. MmyO could have a function in the epoxidation of the desepoxy-
4,5-didehydromethylenomycin A to form methylenomycin A (Fig. 6.5). Evidently, the upper 
chain substituted by an acetyl group and the absence of the C5N moiety have little impact on the 
catalytic function of AsuE1,E2,E3 in the epoxyquinol formation as observed for A8 and A1a, 
respectively. Both the identified C1 and D1 could serve as proper substrates to address the detail 
catalytic aspect of the AsuE1, AsuE2 and AsuE3 enzymes for the further studies. 
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Figure 6.5 The proposed function of MmyO in methylenomycin A biosynthesis. 
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CHAPTER SEVEN:  
 
A TYPE TWO THIOESTERASE AND OTHER ASUKAMYCIN 
BIOSYNTHETIC GENES 
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Background of Thioesterases 
Based on the functional and structural diversity, the thioesterases in metabolic pathways 
are categorized into three groups, type I, type II, and the hotdog-fold thioesterases. Frequently 
located at the C-terminus of the polyketide synthase (PKS) or non-ribosomal polypeptide 
synthase (NRPS) complexes, type I thioesterase (TEI) acts to release the polyketide or 
polypeptide chain from the carrier protein module, either by direct hydration of the thioester 
linkage or by a specific intramolecular cyclization [133-135]. 
Distinct from TEI, the discrete type II thioesterase (TEII) mostly removes the undesirable 
acyl or aminoacyl residues from the catalytic enzyme complex caused by a priming or processing 
error, as these mischarged enzymes can hold back the entire biosynthetic progress (Fig. 7.1) 
[136-139]. Given a high fidelity, an error occurred in any step of the assembly line may cause the 
accumulation of the unprocessed molecule-enzyme complex, and severely block the entire 
biosynthetic process. TEII plays a surveillance role and revives the mischarged carrier protein 
domain, to provide the opportunity for a wanted acyl or aminoacyl unit to bind, as the yields of 
the polyketide and polypeptide products were often considerably impaired in the knockout 
mutants [138, 140-142]. For example, there is 5% of DKxanthenes accumulated in the TEII-
deficient  dkxO mutant compared with the wild type strain of Stigmatella aurantiaca DW4/3-1 
[143]. Besides, the truncation of the McyT TEII resulted in a 95% decreased yield of microcystin 
in Planktothrix agardhii [144]. In some situation, TEII can also remove a true intermediate from 
the intermediate-protein complex. For example, NikP2 TEII tends to discharge β-hydroxyl-His 
from the peptidyl carrier protein NikP1 complex in nikkomycins X/I synthesis of Streptomyces 
tendae Tü901 [145]. 
The hotdog-fold thioesterases consist of a long α-helix wrapped around by five or six 
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anti-parallel β-sheets, reminiscent of a hotdog. They are mainly known to hydrolyze the CoA or 
the carrier protein-tethered acyl substrates for the breakdown of aromatic compounds [146, 147]. 
Not much is known for the rest of family members.  
 
Figure 7.1 Proposed functions of type II thioesterases (TEII). The correct substrates are 
indicated in green; the undesirable intermediate are shown in red. 
 
Results 
Thioesterase Affects the Primed CHC 
Located near the border of the asu cluster, the asuC15 is closely related to a group of 
TEII coding genes found in the polyketide and non-ribosomal peptide biosynthetic gene clusters, 
including RifR and SrfD involved in the rifamycin biosynthesis of Amycolatopsis mediterranei 
and the surfactin formation of Bacillus subtilis, respectively [140, 148]. Mutation and 
biochemical studies indicated that RifR and SrfD discharge the unwanted acyl and aminoacyl 
residues from the carrier protein modules in the assembly lines of rifamycin and surfactin, 
respectively. Interestingly, the asuC15 mutant produced a normal amount of asukamycin A1, yet 
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the yield of the congeners A2-A7 was significantly reduced (Fig. 7.2). This incident is more 
evident by measuring up to 10 times higher production of the CHC-primed asukamycins than the 
total branched acyl-CoA initiated congeners, unlike a relatively equal distribution observed in 
the wild type strain. Since CHC-CoA is not only a building block of asukamycin but can also 
form ω-cyclohexyl fatty acids as membrane components in S. nodosus subsp. asukaensis [10], 
we analyzed the fatty acid compositions of the asuC15 mutant and the wild type strain by GC-
MS (Fig. 7.3, Table 7.1). Notably, 16.5% of ω-cyclohexyl-undecanoic acid (cyclohexyl-C17) was 
detected in the asuC15 mutant, which is at least five-fold higher than the 3.1% detected in the 
wild type strain. Moreover, 1.7% of ω-cyclohexyl-tridecanoic acid (cyclohexyl-C19) fatty acid, 




Figure 7.2 HPLC analysis of the asuC15 mutant and the S. nodosus wild type strain. The 




Figure 7.3 Fatty acid profiles generated by GC-MS analysis. The identified fatty acid 
derivatives are indicated. 
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Iso-C14 10.71 10.84% 2.18% 
Normal-C14 11.04 6.99% 0.00% 
Iso-C15 11.57 6.20% 2.97% 
Anteiso-C15 11.66 17.40% 12.22% 
Normal-C15 11.93 1.52% 1.13% 
Iso-C16 12.57 29.68% 28.54% 
Normal-C16 12.97 9.59% 8.38% 
Iso-C17 13.68 3.68% 5.09% 
Anteiso-C17 13.78 7.76% 18.08% 
Normal-C17 14.14 0.47% 0.59% 
Iso-C18 14.92 0.07% 0.58% 
Normal-C18 15.43 2.72% 2.01% 
Cyclohexyl-C17 15.15 3.06% 16.52% 
Cyclohexyl-C19 18.04 0.04% 1.71% 
 
Other asu Gene Functions  
The AsuC6, a second thioesterase-like protein, belongs to the type of hotdog-fold 
thioesterases, which presumably have a role to hydrolyze the thioester bond and release the acyl 
intermediate from the PKS enzyme complex [146, 147]. The asuC6 mutant has not yet been 
constructed and the precise function of AsuC6 function remains to be clarified. Located between 
the asuR group genes and asuE1, asuC1 encodes for a phosphopantetheinyl transferase (PPTase), 
which likely primes the apo-ACP by the covalently attaching a 4'-phosphopantetheine moiety of 
CoA to give a holo-ACP. Since bacteria always utilizes orthogonal carrier protein recognition as 
a strategy to distinguish primary metabolism from secondary metabolism [149], AsuC1 might be 
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a dedicated PPTase to prime the asu ACPs, AsuC5, C11 and C12, involved in the lower and 
upper chain biosynthesis. 
AsuM1, a homolog of numerous antibiotic efflux exporters, could release the synthesized 
asukamycin products from the cells. AsuR1-R6, discretely detected at the two border regions of 
the cluster, show homology to numerous putative transcriptional regulator genes found in Gram-
positive bacteria. AsuR1 and AsuR6 are closely related to the LuxR-type transcriptional 
regulators [150]. AsuR2 is likely a TetR-like transcriptional regulator [151]. AsuR3 is a putative 
integral membrane sensor protein, which could work together with the DNA binding protein 
AsuR4 [152]. AsuR5 belongs to the Streptomyces antibiotic regulatory proteins (SARP) [153]. 
As many antibiotic biosynthesis gene clusters contain one or multiple regulatory genes, AsuR1-
R6 could have regulatory functions to control the asukamycin biosynthetic gene activities. 
AsuH1 is a putative ORF with an unknown function. 
Discussion 
CHC-CoA is not only the substrate for the PKS AsuC3,C4 in A1 upper chain assembly, 
but is also recruited by the FAS complex and assembled into ω-cyclohexyl fatty acids which 
account for 3.1% of total cellular fatty acids in S. nodosus subsp. asukaensis [10]. The CHC-
CoA utilization to form asukamycin A1 and ω-cyclohexyl fatty acids does not occur in a fixed 
ratio, as A1 was increased to more than 80% of total asukamycins, while ω-cyclohexyl fatty 
acids were kept under 25% of total fatty acids upon feeding excess cyclohexanecarboxylic acid 
[10]. For this inconsistent incorporation rate of the CHC substrate to the cellular membrane fatty 
acids and the asukamycin products, one explanation is the distinct substrate specificities of FabH 
and AsuC3,C4. While FabH prefers the branch chain acyl-CoA starters, AsuC3,C4 favors the 
CHC-CoA. A second reason is likely the AsuC15 TEII action to release the tethered 
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cyclohexylpropanoate from the FAS-ACP and allow the recruitment of more branched chain 
acyl-CoA starters, as the percentage of ω-cyclohexyl fatty acids was increased five-fold in the 
asuC15 mutant. The cellular membrane fluidity is probably affected by variations in the content 
of ω-cyclohexyl fatty acids via changing the phase transition temperature, as observed for several 
thermo-acidophilic bacteria, which may contain up to 90% of ω-cyclohexyl fatty acids [65, 66, 
154]. Thus AsuC15 could suppress excessive ω-cyclohexyl fatty acid formation, which helps to 
maintain the membrane homeostasis and structural integrity, particularly when the cellular level 
of CHC-CoA is rising. Evidently, AsuC15 can also discharge the CHC-acyl intermediate from 
AsuC5-ACP to enhance the production of congeners A2-A4, as the asuC15 mutant 
predominantly accumulates A1, rather than an equal amount of A1 and A2-A4 observed in the 
wild type. 
AsuC6, the other thioesterase in the asu cluster, is a hotdog-fold thioesterase. The most 
studied hotdog-fold thioesterase, the PaaI from E. coli, hydrolyzes the phenylacetyl-CoA to 
liberate CoA from the dead-end products [146]. Similarly, the AsuC6 could be responsible for 
A1a-A5a accumulation in the asuD1, D2 and D3 mutants, which are supposed to be tightly 
bound to the ACP AsuC11 in the absence of a thioesterase (Fig. 7.4). In fact, as the coronatine 
and aminocoumarin biosynthesis involve amide-bond formation between an amine with the free 
acid substrates rather than a carrier protein tethered acyl group [155, 156], the similar acylation 
of the C5N moiety could require a free carboxylic acid rather than a carrier protein tethered lower 
chain intermediate. If so, AsuC6 could release the triene lower polyketide from the carrier 
protein in the wild type strain (Fig. 7.4). This seems contradictory to the previous A1a feeding 
experiments, which ruled out the lower polyketide intermediate containing free carboxylic group, 
[20]. However, the feeding result should be treated with caution, as the non-incorporation could 
result from a low permeability of the fed compound. 
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Figure 7.4 The proposed function of AsuC6. 
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SUMMARY AND FUTURE PROSPECT 
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Summary 
Prior to this study, the extensive feeding experiments have been performed to reveal the 
biosynthesis of manumycin A and asukamycin. The structure elements of asukamycin, including 
a mC7N core, a cyclohexane moiety, and a C5N ring, were proposed to arise from the 
corresponding 3,4-AHBA, shikimic acid, and 5-ALA [20, 60, 157]. The lower and upper triene 
polyketide chains are likely built up from 3,4-AHBA and CHC-CoA, respectively, through three 
steps of classical polyketide condensations. However, the biosynthetic genes involved in 3,4-
AHBA, CHC-CoA, and triene chain assembly of asukamycin, have yet been uncovered. Until 
now, the asuD2 (hemA-asuA) was the only reported gene to work on the C5N moiety 
biosynthesis of asukamycin [21]. As the epoxyquinoid structure of the mC7N core is essential for 
the biological activities for the manumycin metabolites, the post-assembly oxygenation of 
protoasukamycin also attracts massive attention [20, 38, 76].  
In this study, the cloning, mutagenic analysis and characterization of the asukamycin 
biosynthetic genes have been carried out in S. nodosus subsp. asukaensis (Fig. 8.1). To 
summarize, the lower polyketide chain is initiated with 3,4-AHBA, the condensation product of 
ASA and DHAP through the catalytic activities of AsuA3 and A1, while the upper chain is 
started with the CHC-CoA, which is derived from the shikimate precursor by the action of the 
AsuB group enzymes. The 3,4-AHBA is adenylated by AsuA2, loaded on the ArCP AsuC12, 
and consecutively condensed with three malonyl extenders by PKS AsuC13,C14 and the 
corresponding reducing enzymes, KR AsuC7 and DH AsuC8,C9, to give a trans triene. 
Concomitantly, the CHC-CoA is primed by a set of PKSIII AsuC3,C4 and extended with two 
additional malonyl-CoA to form a trans triene upper chain. The ACP tethered lower chain 
intermediate is linked with the polyketide upper chain by AsuC2, and further attached with a
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Figure 8.1 Proposed asukamycin biosynthetic pathway. The primary metabolite substrates are shown in squares. The ACP and aroyl 
carrier protein are in capsules.
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nascent C5N moiety by AsuD1-D3. The resulted protoasukamycin is subsequently introduced a 
hydroxy and an epoxide groups by AsuE1/E2 and AsuE3, respectively, to form the final product 
asukamycin. Moreover, the AsuC15 type II thioesterase has a function to suppress the formation 
of ω-cyclohexyl fatty acid byproducts and likely maintain the homeostasis of the cellular 
membrane. Besides, a plausible crosstalk of the biosynthesis between the fatty acids and the 
asukamycin metabolites is also proposed. 
Future Prospects  
The manumycin metabolites hold great promise in pharmaceutical treatments due to their 
unique structural moieties. In this work, the genetic and biochemical results set a stage for the 
further work to investigate the molecular mechanism of each catalytic step, especially, the 
pathway-specific biosynthetic enzymes. This information not only allows us to identify and 
study the biosynthetic enzymes for other manumycin metabolites, but also shed lights on the 
further bioengineering of the manumycin family compounds.  
The Uncharacterized Asukamycin Biosynthetic Genes 
Although a majority of the asu genes have been investigated by mutagenesis or 
biochemical analysis, the functions of several biosynthetic genes remain elusive. To access these 
genes, we can take advantage of the established pART1391 to construct a gene-knockout series 
of the pART1391 derivatives, which can be introduced and expressed in S. lividans, following a 
similar procedure to the case for pART1361-E3 described in chapter 6. If the corresponding 
transformant strains display distinct metabolic profiles compared with that of the wild type, these 
genes could be critical for the asukamycin biosynthesis.  
Located downstream of asuC13, the asuC14 encodes a protein highly related to PKS 
AsuC13, except for a truncated N-terminus and lack of a putative catalytic triad. To address the 
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function role of AsuC14, we can create an asuC14 mutant, which might fail to give any 
asukamycin product if AsuC14 function together with AsuC13 on the Claisen condensation. As 
the iterative type II PKS is frequently paired with its ortholog, a chain length factor (CLF), it is 
likely that AsuC14 forms a confined tunnel with AsuC13 to accommodate the growing triene 
polyketide.  Under this assumption, the asuC14 mutant could generate a new set of asukamycin 
derivatives with various lower chains, such as diene, tetraene, or pentene.  
AsuC6, a hotdog-fold thioesterase, could also play a role in controlling the lower chain 
biosynthesis. This functional activity of AsuC6 can be verified by gene inactivation. If the 
majority of asukamycin production was abolished by this mutation, AsuC6 could catalyze the 
hydrolysis of the thioester bond to release the lower polyketide from the ACP AsuC11 (Fig. 7.4). 
In this case, it is worthwhile to question whether AsuC6 has a substrate preference towards the 
triene chain to a premature diketide or triketide intermediate. Therefore, a series of di-, tri-, and 
tretraketides can be synthesized and linked to the CoA analog, N-acetyl cysteamine (SNAC), for 
a further in vitro enzymatic evaluation, where a significantly higher catalytic activity on the 
tretraketide than the di- or triketide would suggest the participation of AsuC6 in the chain length 
control. 
The only set of the PKS reducing enzymes in the asu cluster, the ketoreductase AsuC7 
and the dehydratases AsuC8,C9, were proposed to function in the compilation of the triene 
polyketides. The asuC7 or asuC8,C9 mutants likely fail to produce asukamycin and congeners. 
These mutants may only accumulate 3,4-AHBA rather than the asukamycin derivatives 
containing trioxo- or trihydroxy-polyketide chains, as the downstream type II PKS AsuC13,C14 
may reject the 3-oxodiketide or 3-hydroxydiketide intermediates, which seize the asu ACPs and 
block the downstream synthesis. Besides, the plausible involvement of AsuC7 and AsuC8,C9 in 
the upper chain biosynthesis can also be justified by checking the presence of E1 and E3/E4 
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metabolites accumulated in the mutants. If so, the absence of these reducing enzymes should 
ultimately add to the production of cyclohexyl fatty acids, or even form the 3,4-AHBA initiated 
fatty acids. To date, there is no reported 3,4-AHBA initiated fatty acids, which might be detected 
in the asuC7 mutant, asuC8,C9 mutant, or the previously constructed asuA2 and asuC11C12 
mutants.  
Besides these structural biosynthetic genes, the resistant genes have yet been clarified in 
the asu cluster. Functional expression of the pART1391 in S. lividans indicated that these cloned 
asu genes are sufficient to convey the self-immunity of asukamycin. A major facilitator 
superfamily (MFS) transporter, AsuM1, has been found and proposed to serve as an antibiotic 
efflux transporter to free the nascent asukamycin products from the cells. The asuM1 can be 
inactivated in pART1361 and pART1361-E3 to give the pART1361-M1 and pART1361-E3M1, 
respectively, which were separately introduced into S. lividans. Presumably, the transformant 
carrying a pART1361-M1 is lethal, or displays severe growth retardation, while the pART1361-
E3M1 may produce 4-hydroxyprotoasukamycins, D1-D5, as a quinol structure of the premature 
D1-D5, unlike the expoxyquinol core of asukamycin, exhibits no cytotoxicity. 
Mutation study indicated that the AsuC15 TEII suppresses the formation of the ω-
cyclohexyl fatty acids and likely maintains the homeostasis of the cellular membrane. We 
assumed that AsuC15 releases the tethered 3-cyclohexylpropanoate from the FAS-ACP, which 
allows the recruitment of the branched chain acyl-CoA starters. To confirm this novel activity, 
the asuC15 can be cloned into the shuttle vector pIJ622 under the control of the constitutive 
ermE* promoter to generate pART1401, which is further expressed in S. lividans. The resulted 
transformant of S. lividans/pART1401 can be fed with cyclohexanecarboxylic acid and analyzed 
the cellular level of ω-cyclohexyl fatty acids, which is expected to be lower than that in the S. 
lividans carrying a control empty vector. Moreover, we can perform an enzymatic assay using 
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the recombinant AsuC15 to hydrolyze the 3-cyclohexylpropanyl-ACP, which could be 
synthesized from a 3-cyclohexylpropanyl-SNAC and a FAS-ACP by the malonyl-CoA:ACP 
transacylase SgFabD of Streptomyces glaucescens [158]. AsuC15 should display higher catalytic 
activity towards the 3-cyclohexylpropanyl-ACP than a butyryl-ACP or 4-methylpentanyl-ACP, 
the ubiquitous intermediates for Streptomyces fatty acid biosynthesis. 
The Biosynthesis of Other Manumycin Metabolites 
Despite that the biosynthetic genes involved in the C5N moiety and CHC-CoA 
assemblage are closely positioned and appears to be co-transcribed, many functionally related 
asu genes are not organized in an apparent order in the cluster (Fig. 2.1). For instance, the key 
genes asuA1 and asuA3 performing the 3,4-AHBA formation are alienated by eight unrelated 
ORFs and belong to two separated transcription units, whereas the equivalent griI and griH 
position side by side and possibly share the same transcript engaged in the grixazone production 
in S. griseus [59]. This implies that the acquired asukamycin biosynthesis has evolved through 
multiple horizontal gene transfer events and possibly an extensive genomic rearrangement in S. 
nodosus, which could be further confirmed by comparison with other closely related manumycin 
biosynthetic gene clusters.  
As the majority of other manumycin metabolites share an mC7N core as well as a C5N 
moiety, we can probe with the asuA, asuD, and asuE group genes to find the corresponding 
biosynthetic genes, such as the ones for manumycin A and colabomycin from S. parvulus Tü64 
and Streptomyces griseoflavus Tü2880, respectively. Notably, S. griseoflavus Tü2880 produces 
solely colabomycins that possess a trans tetraene lower polyketide, while S. nodosus 
accumulates asukamycins and congeners containing an identical lower triene chain. This 
structural disparity of triene and tetraene suggests that these two strains employ distinct enzyme 
systems to control the length of the lower polyketide chain (Fig. 8.2). The colabomycin producer 
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might develop the specified type II PKS components to set up a larger binding pocket than that 
of the AsuC13,C14, to accommodate a tetraene polyketide chain. In addition, a hotdog-fold 
thioesterase could play a key role to release the ACP tethered tetraene rather than triene for the 
colabomycin lower chain assembly. 
 
Figure 8.2 Structures of manumycin metabolites from S. nodosus asukaensis, S. parvulus 
Tü64, and S. griseoflavus Tü2880. 
 
The most diverse building block of the manumycin metabolites is the upper polyketide 
chain. Instead of a CHC-primed triene chain, manumycin A-C opens the upper tetraketide 
assembly using an ACP-tethered butyryl substrate, likely a fully-reduced fatty acid intermediate 
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resulted from the action of FabH in S. parvulus (Fig. 8.2). Butyryl-CoA is also employed as a 
building starter of several polyketide products, including R1128 [159], murayaquinone [160], 
FD-594 [161], and sulfurmycinone [162]. After the initiation process, the nascent diketide 
intermediates of manumycin A and B are further extended through three and two runs of 
condensations using methylmalonyl-ACPs, respectively. Alternatively, manumycin C differs 
from manumycin A at the third extender unit, a malonyl-ACP rather than the methylmalonyl-
ACP. This promiscuity could be resulted from three aspects: 1). a limited supply of the 
methylmalonyl substrate; 2). a low stringency of the polyketide condensation enzyme; 3). a low 
specificity of the downstream amide synthase, an AsuC2 homolog. To test the first possibility, an 
extra amount of methylmalonate and malonate can be add to the culture of S. parvulus, and an 
increasing production ratio of manumycin A against B and C could specify the consequence due 
to a shortage of methylmalonyl substrate. Since the condensation enzymes involved in 
asukamycin upper chain formation has not been fully addressed, it is worthwhile to target other 
PKS genes in the manumycin gene cluster. Besides, we should be aware of the amide synthase, a 
asuC2 homolog, which could process a premature triketide to form manumycin C. Furthermore, 
the saturated configuration on the C5,C6 position of the manumycin A upper chain is expected to 
arise from the action of an additional reductase, which could function independently or 
immediately after the formation of the diketide with a fixed stereospecificity.   
Synthesis of the Unnatural Asukamycin Metabolite 
To expand the diversity of the metabolites, one approach is to supplement the synthetic 
precursors to fermentation cultures. For example, the alicyclic carboxylates with a variable ring 
size has been fed and resulted in the production of the novel asukamycin analogs, containing 
various cyclic ring structures to substitute the cyclohexane moiety in S. nodosus [10]. However, 
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this could be ineffective due to the competition between these synthetic precursors and the 
natural CHC-CoA. In this study, the constructed asuB1 mutant, which failed to form the CHC-
CoA, provides a better platform for these feeding approaches mentioned above than the wild 
type strain. 
Moreover, the constructed asuA3 and asuA1 mutants with the 3,4-AHBA deficiency can 
be used to synthesize many asukamycin analogs by feeding 3,4-AHBA analogs, such as 3,5-
AHBA, 3-aminobenzoic acid  (Fig. 8.3). These analogs bear a distinct core structure to replace 
the native mC7N moiety, which could lead to novel biological activities, as the epoxyquinoid 
feature was proposed to convey the antimicrobial activities for manumycin metabolites. Besides, 
these feeding experiments can also justify the specificity of the AsuE1-E3 oxygenases, in which 
the oxidized core points toward that these oxygenases are capable of processing the 
corresponding 3,4-AHBA derivative. 
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Figure 8.3 Confirmed or postulated asukamycin analogs obtained by feeding the asuA3 or 
asuA1 mutants with diverse aromatic precursor. The solid arrows indicate previously 
reported or partially confirmed feeding results, while the dashed arrows show the possible 
derivatives. 
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Bacterial Strains and Chemicals 
S. nodosus subsp. asukaensis ATCC 29757 was obtained from the American Type 
Culture Collection. S. lividans K4-114 was kindly provided by Dr. C. Khosla. E. coli strains 
were obtained from the John Innes Center (Norwich, UK). Media and chemicals were purchased 
from Difco, Sigma Aldrich and EMD. All chemicals and solvents were of reagent or HPLC 
grade and were used without further purification unless otherwise mentioned. 
Fermentation and Analysis of the Asukamycin Metabolites 
Fermentation and Feeding Experiments 
Wild type and mutant strains of S. nodosus subsp. asukaensis were cultivated with freeze 
storage spores in 25 mL YMG medium  in 250 mL baffled flasks with coil on a rotary shaker at 
250 rpm and 28°C for 2-3 days [20, 110, 163]. The presence of the asukamycin products was 
confirmed by the bioassay against the growth of Staphylococcus aureus. S. lividans K4-114 
recombinant strains were cultured in 25 mL R5 or MS  medium for 4-5 days [163]. If required, 
the media were supplemented with the selective antibiotics at following the concentrations: 
apramycin (50 µg/mL); kanamycin (20 µg/mL); spectinomycin (50 µg/mL). Feeding 
experiments with 3,4-AHBA (100 µg/mL) and 4-hydroxyprotoasukamycin (20 µg/mL) were 
conducted by adding these compounds to one day-old cultures and harvesting one day later. 
HPLC and LC-MS Analysis 
Fermented cultures were mixed thoroughly with an equal volume of ethyl acetate. 
Separated by centrifugation, the ethyl acetate layer was collected and evaporated to near dryness. 
The crude extract was dissolved in an equal volume of methanol and analyzed using a P680 
HPLC system (Dionex, Sunnyvale, CA USA) and an XTerra RP18 column (4.6 X 250 mm, 
Waters) at a flow rate of 0.5 mL/min at 25°C. Twenty µL of crude extract were injected, 
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equilibrated with 65% solvent B (acetonitrile with 0.1% formic acid) in solvent A (water with 
0.1% formic acid) for 5 min, developed with a gradient of 65-90% solvent B in solvent A for 20 
min and washed with 90% solvent B in solvent A for 10 min. To analyze the asuD1-D3 mutants, 
a gradient of 50-70% solvent B in solvent A was applied instead. The extraction and HPLC 
analysis of 3,4-AHBA followed the described protocol [59]. 
High resolution MS and LC-MS analyses were carried out on a 6210-TOF LCMS system 
(Agilent Technologies Inc., Santa Clara, CA USA), in which the LC was performed using a 
XDB C18 (4.6 X 50 mm, 1.8 micron particle size) high throughput column (Agilent technologies, 
Inc.) with the same elution program as the HPLC analysis mentioned above. The exact masses of 
the identified compounds are listed in Table 9.1. 
Fatty Acid Analysis 
 The mycelia of the fermentation cultures were collected, washed three times with 10% 
glycerol and mixed with 3 mL MeOH:CHCl3 (2:1) in a glass homogenizer. The mixture was 
separated by centrifugation, and the supernatant was further rinsed three times with 1 mL of 
water. The organic layer was extracted, hydrolyzed and the methyl esters of the fatty acids were 
prepared [164, 165]. The GC-MS analysis was conducted on a Trace Gas Chromatograph 
(Thermo Quest Inc. Schaumburg, IL, USA) using a 30 m x 0.25 mm DB-225 column with a 0.15 
m film thickness (J&W Scientific, Folsom, CA). The flow rate of the carrier gas ultrapure helium 
was 1.5 ml/min and the GC program was as follows: 60°C for 1 min; 15°C/min to 200°C; 
5°C/min to 260°C and hold for 10min. The peak areas were recorded by XCalibur-Qual Browser 
software (Thermo Quest Inc. Schaumburg, IL, USA). The signals of the fatty acid methyl esters 















A1 C31H34N2O7 546.2366 546.2360 1.19 189.13 
A2 C28H30N2O7 506.2053 506.2062 1.78 149.09 
A3, A4 C29H32N2O7 520.2210 520.2228 3.62 163.11 
A5 C30H34N2O7 534.2366 534.2377 2.05 177.13 
A6, A7 C31H36N2O7 548.2523 548.2530 1.36 191.14 
B1 C31H36N2O7 548.2523 548.2528 0.91 189.13 
B2 C28H32N2O7 508.2210 508.2229 3.74 149.10 
B3, B4 C29H34N2O7 522.2366 522.2382 3.06 163.11 
B5 C30H36N2O7 536.2523 536.2517 1.02 177.13 
C1 C31H34N2O5 514.2468 514.2477 1.73 189.13 
C2 C28H30N2O5 474.2155 474.2163 1.68 149.10 
C3, C4 C29H32N2O5 488.2311 488.2317 1.15 163.11 
C5 C30H34N2O5 502.2468 502.2477 1.77 177.13 
D1 C31H34N2O6 530.2417 530.2422 0.90 189.13 
D2 C29H32N2O6 504.2260 504.2254 1.25 149.10 
D3, D4 C28H30N2O6 490.2104 490.2110 1.34 163.11 
D5 C30H34N2O6 518.2417 518.2411 1.06 177.13 
A8 C20H20N2O7 400.1271 400.1289 4.73 --- 
B8 C20H22N2O7 402.1427 402.1444 4.19 --- 
C8 C20H20N2O5 368.1372 368.1394 6.02 --- 
A1a C26H29NO6 451.1995 451.2010 3.44 189.13 
A2a C23H25NO6 411.1682 411.1657 6.13 149.09 
A3a,A4a C24H27NO6 425.1838 425.1804 8.13 163.11 
A5a C25H29NO6 439.1995 439.1990 1.09 177.12 
B1a C26H31NO6 453.2151 453.2171 4.43 189.13 
B2a C23H27NO6 413.1838 413.1801 8.93 149.09 
B3a, B4a C24H29NO6 427.1995 427.1956 9.19 163.10 
B5a C25H31NO6 441.2151 441.2120 7.05 177.12 
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Purification and NMR Analysis of D1 and B8 
A reliable yield of the novel intermediate 4-hydroxyprotoasukamycin D1 was obtained in 
S. lividans K4-114 carrying pART1361E3, which was generated from pART1361 with the λ-Red 
PCR strategy by replacing asuE3 with a spectinomycin resistance gene. S. lividans K4-
114/pART1361E3 was inoculated into 500 mL MS medium in 2-liter flasks with a coil and 
fermented on a rotary shaker at 250 rpm and 28°C for 4-5 days. One liter of harvested culture 
was extracted three times with an equal volume of ethyl acetate, and the combined ethyl acetate 
extract was dried, concentrated and purified on a silica gel column (100-200 mesh), eluting with 
dichloromethane/methanol (100:3). The compound D1 fraction was collected and further 
purified by semi-preparative C18 reverse-phase HPLC (Dionex), eluting with 75-85% solvent C 





C-NMR, HSQC and HMBC spectra were recorded in DMSO-d6 on a Varian System 700 
spectrometer (Table 6.1). 
To purify the B8, the asuC2 mutant was inoculated into 50 mL YMG medium in 250 mL 
flasks with coils and fermented at 250 rpm and 28°C for 3 days. One liter of harvested culture 
was extracted three times with an equal volume of ethyl acetate. The combined ethyl acetate 
extract was dried, concentrated and purified on a silica gel column (100-200 mesh), eluting with 
dichloromethane/methanol (90:10). The compound B8 fraction was further purified by semi-
preparative C18 reverse-phase HPLC (Dionex), eluting with 35-50% solvent C in solvent A, and 




C-NMR spectra were recorded in 
DMSO-d6 on a Varian System 700 spectrometer (Table 4.1). 
Genomic Library and Mutant Construction 
Molecular biology procedures and DNA manipulations were carried out according to 
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standard protocols. The cosmid genomic library of S. nodosus subsp. asukaensis was constructed 
by cloning the Sau3AI partially digested genomic DNA into pOJ446, an E. coli-Streptomyces 
shuttle vector.  Ligation mixtures were further packaged with the Gigapack III Gold Packaging 
kit (Stratagene) and transfected into E. coli SURE strain (Stratagene). Two 
32
P-labled DNA 
probes, the chcA and asuD2 genes, were used for screening the constructed cosmid library.  
To construct mutants by antibiotic resistance gene insertion, the target gene-containing 
DNA fragment was cloned into the BamHI site of the pGM160 vector [163]. The internal coding 
region with or without the junction region were deleted or replaced with either the 1.4 kb 
apramycin resistance gene or the 0.8 kb kanamycin resistance gene from pOJ446 or pBluescript, 
respectively (Fig. 9.1) [163]. The truncated plasmid clones were delivered by polyethylene 
glycol-based transformation into S. nodosus subsp. asukaensis, and integrated into the 
chromosome forced by incubating the transformants at 39°C with continuing selection for 
thiostrepton resistance. One or two rounds of streaking at 39°C in the absence of thiostrepton 
allowed the identification of thiostrepton-sensitive strains, in which the targeted genes were 
replaced with the antibiotic resistance gene. The resulting recombinants were further confirmed 
by Southern hybridization analysis (Fig. 9.1), except for the mutant asuA2, which was verified 
by chromosome walking and genomic sequencing. 
To construct the asuE1 mutant, the 1.5 kb upstream and downstream regions, including 
100 bp of asuE1, were amplified by PCR and tandem cloned in the pHGF9050 vector. The four 
oligonucleotide primers used, AsuE1-1 to -4, are listed in Table 9.2. The resulting pART1334 
was transformed into E. coli ET12567/pUZ8002 and conjugated with S. nodocus subsp. 
asukaensis wild type [163]. The apramycin resistant recombinants resulting from the 
homologous recombination between the plasmid and the wild type S. nodosus were further 
selected, subcultured in MS liquid medium for 1-2 rounds, and screened for apramycin sensitive 
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recombinants derived from a second crossover event. The double crossover recombinant was 
confirmed by Southern hybridization analysis (Fig. 9.1). 
Table 9.2 Oligonucleotide primers used for the mutant constructions and λ-Red 
recombinations. 
Primers Sequence from 5’ to 3’ 































Figure 9.1 Southern blots of thirteen constructed mutants. Hybridization probes and 












Reassembly and Heterologous Expression of the Cloned asu Cluster 
The E. coli BW25113/pIJ790 was cultivated in LB medium supplemented with 25 µg/mL 
chloramphenicol plus 10 mM L-arabinose at 28°C [89]. When the OD600 reaches 0.6, the E. coli 
cells were harvested, washed with ice-cold 10% glycerol for three times, concentrated and 
stocked in the ice-cold GYT (10% glycerol; 0.125% yeast extract; 0.25% tryptone). The cosmid 
clones 2B9 and 10D6 were linearized by restriction digestion with SpeI and EcoRI, respectively, 
equally mixed and introduced into E. coli BW25113/pIJ790 by electroporation. The cells were 
then added to 1 mL SOC [89], recovered at 37°C for 3 hours, and plated out onto LB agar with 
100 µg/mL apramycin. For the negative control, the linearized 2B9 and 10D6 were transformed 
separately by the same procedure. The recombinant clone was confirmed by matching the 
anticipated EcoRI digestion pattern and named pART1361 (Fig. 2.2). Intergeneric conjugation of 
the recombinant cosmids from E. coli to S. lividans K4-114 followed the established protocol 
[163]. 
To construct pART1391, a 1.5 kb DNA fragment from pIJ778 was PCR-amplified using 
primers AsuRED-4 and -6 (Table 9.2) to carry a spectinomycin resistance gene cassette plus two 
50-bp nucleotides, designed to be identical to the boundaries of the targeted region on 
pART1361 (Fig. 2.3) [89]. To obtain the recombinant strain, the gel-purified PCR fragment was 
introduced into E. coli BW25113/pART1361/pIJ790 by electroporation, and the transformants 
were screened for spectinomycin resistance. The deletion in the resulting clone was confirmed by 
matching up to the expected EcoRI digestion pattern and verified by PCR. The pART1361E3 
construction followed the same strategy as described above but using primers AsuRED-E3F and 
-E3R (Table 9.2). 
To insert the point mutation that modifies the TCC (Ser) codon into ACC (Thr) in the 
asuD2 gene, the internal fragment containing the BamHI-KpnI sites was PCR-amplified using  
101 
primers S83TF and S83TR (Table 9.2). The BamHI-KpnI-cleaved fragment was then used to 
replace the corresponding region in the pALS3 plasmid. The further steps were identical with the 
pALS4 construction [21]. 
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